

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2026
OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number: 001-39463

Ouster, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

86-2528989
(I.R.S. Employer
Identification No.)

350 Treat Avenue
San Francisco, California 94110
(Address of principal executive offices) (Zip Code)
(415) 949-0108
(Registrant's telephone number, including area code)

N/A
(Former name, former address, and former fiscal year, if changed since last report)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$0.0001 par value per share	OUST	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
Emerging growth company	☐		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 31, 2026, the registrant had 72,112,333 shares of common stock, \$0.0001 par value per share, outstanding.

TABLE OF CONTENTS

	Page
Part I - Financial Information	
<u>Item 1.</u>	5
<u>Financial Statements</u>	5
<u>Condensed Consolidated Balance Sheets (Unaudited)</u>	5
<u>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</u>	6
<u>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</u>	7
<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u>	8
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	10
<u>Item 2.</u>	30
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	30
<u>Item 3.</u>	43
<u>Quantitative and Qualitative Disclosures About Market Risk</u>	43
<u>Item 4.</u>	44
<u>Controls and Procedures</u>	44
Part II - Other Information	
<u>Item 1.</u>	45
<u>Legal Proceedings</u>	45
<u>Item 1A.</u>	45
<u>Risk Factors</u>	45
<u>Item 2.</u>	45
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	45
<u>Item 3.</u>	45
<u>Defaults Upon Senior Securities</u>	45
<u>Item 4.</u>	45
<u>Mine Safety Disclosures</u>	45
<u>Item 5.</u>	45
<u>Other Information</u>	45
<u>Item 6.</u>	46
<u>Exhibits</u>	46
<u>Signature</u>	47

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Ouster, Inc. (the “Company”, “Ouster,” or “we”) intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this Quarterly Report other than statements of historical fact, including, without limitation, statements regarding: expected contractual obligations and capital expenditures; the capabilities of and demand for Ouster’s products; Ouster’s anticipated new product launches and developments, including software-related solutions systems, and the timing for those launches and developments; the anticipated benefits and synergies of strategic transactions, including the Stereolabs acquisition, and expected integration efforts; the impact of tariffs and trade policy actions on Ouster’s costs, supply chain, and customer demand; Ouster’s ability to grow its sales and marketing organization; Ouster’s future results of operations, cash reserve and financial position; projected industry and business trends; potential risks of inventory obsolescence; Ouster’s future business strategy, plans, distribution partnerships, market growth and its objectives for future operations, including executing towards profitability; Ouster’s competitive market position within its industry and the impact of market conditions and other macroeconomic factors on Ouster’s business, financial condition and results of operation, foreign currency exchange rate fluctuations and the effectiveness of hedging activities, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” “aim,” “forecast,” “should,” “can have,” and similar expressions are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties, and assumptions that may cause actual results to differ materially from those that Ouster expected, including, but not limited to, Ouster’s limited operating history and history of losses; substantial research and development costs needed to develop and commercialize new products; Ouster’s ability to overcome its limited sales history and establish and maintain confidence in its long-term business prospects; fluctuations in its operating results; Ouster’s ability to maintain competitive average selling prices or high sales volumes or reduce product costs; conditions in its customers’ industries; the competitive environment in which Ouster operates; the negotiating power and product standards of its customers; the inclusion of its products in target markets; the creditworthiness of Ouster’s customers; the ability of its lidar technology roadmap and new software solutions to catalyze growth; the selection of Ouster’s products for inclusion in target markets; risks of product delivery problems or defects; costs associated with product warranties; Ouster’s future capital needs and ability to secure additional capital on favorable terms or at all; inaccurate forecasts of market growth; Ouster’s ability to manage growth; Ouster’s ability to grow its sales and marketing organization; risks related to international operations, including international manufacturing; cancellation or postponement of contracts or unsuccessful implementations; Ouster’s ability to maintain inventory and the risk of inventory write-downs; its ability to use tax attributes; Ouster’s dependence on key third-party suppliers, in particular Benchmark Electronics, Inc. (“Benchmark”), Fabrinet and other suppliers; and its supply chain constraints and challenges; adverse conditions in the industries Ouster targets or the global economy more generally; Ouster’s ability to recruit and retain key personnel; risks related to acquisitions, including integration risks and the failure to achieve anticipated benefits; risks related to the use of AI tools by us and others, including risks related to product performance, cybersecurity and data privacy; Ouster’s ability to effectively respond to evolving regulations and standards; Ouster’s ability to adequately protect and enforce its intellectual property rights, including as it relates to Hesai; the impact of political events, trade and other international disputes and geopolitical tensions and other business interruptions on Ouster’s business; changes to trade policy, tariffs, and import/export regulations; risks related to operating as a public company; and other important factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, that are further updated from time to time in the Company’s other filings with the Securities and Exchange Commission (the “SEC”), including this Quarterly Report, that may cause its actual results, performance or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements.

Any forward-looking statements made herein speak only as of the date of this Quarterly Report, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance, or achievements reflected in the forward-looking statements will be achieved or occur. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements for any reason after the date of this Quarterly Report or to conform these statements to actual results or revised expectations.

GENERAL

Unless the context otherwise requires, references in this Quarterly Report to the terms “Ouster,” “the Company,” “we,” “our” and “us” refer to the business and operations of Ouster, Inc.

We may announce material business and financial information to our investors using our investor relations website at <https://investors.ouster.com>. We therefore encourage investors and others interested in Ouster to review the information that we make available on our website, in addition to following our filings with the SEC, webcasts, press releases and conference calls. Information contained on our website is not part of this Quarterly Report.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

OUSTER, INC. **CONDENSED CONSOLIDATED BALANCE SHEETS** **(unaudited)** **(in thousands, except share and per share data)**

	June 30, 2026	December 31, 2025
Assets		
Current assets:		
Cash and cash equivalents	\$ 91,759	\$ 67,413
Restricted cash, current	336	1,467
Short-term investments	169,322	141,172
Accounts receivable, net	22,096	27,753
Inventory	31,429	23,566
Prepaid expenses and other current assets	30,743	17,517
Total current assets	345,685	278,888
Property and equipment, net	35,241	31,891
Operating lease, right-of-use assets	13,022	13,452
Unbilled receivable, non-current portion	5,254	8,560
Goodwill	38,525	—
Intangible assets, net	32,908	13,316
Restricted cash, non-current	1,100	1,100
Other non-current assets	3,083	2,309
Total assets	\$ 474,818	\$ 349,516
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	\$ 22,315	\$ 19,984
Accrued and other current liabilities	38,759	26,200
Contract liabilities, current	17,166	20,705
Operating lease liability, current portion	4,780	4,142
Total current liabilities	83,020	71,031
Operating lease liability, non-current portion	11,617	12,938
Contract liabilities, non-current portion	3,324	3,106
Deferred tax liability	4,936	—
Other non-current liabilities	613	703
Total liabilities	103,510	87,778
Commitments and contingencies (Note 7)		
Stockholders' equity:		
Common stock, \$0.0001 par value; 200,000,000 and 100,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 68,489,797 and 60,947,757 issued and outstanding at June 30, 2026 and December 31, 2025, respectively	48	48
Additional paid-in capital	1,381,020	1,235,580
Accumulated deficit	(1,009,027)	(973,448)
Accumulated other comprehensive (loss) income	(733)	(442)
Total stockholders' equity	371,308	261,738
Total liabilities and stockholders' equity	\$ 474,818	\$ 349,516

The accompanying notes are an integral part of these condensed consolidated financial statements

Note: Amounts as of December 31, 2025 are derived from the December 31, 2025 audited consolidated financial statements.

OUSTER, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Revenue:				
Product revenue	\$ 52,763	\$ 35,015	\$ 100,994	\$ 66,120
Royalties	1,863	34	2,210	1,561
Total revenue	54,626	35,049	103,204	67,681
Cost of revenue	27,941	19,207	55,681	38,356
Gross profit	26,685	15,842	47,523	29,325
Operating expenses:				
Research and development	19,341	17,147	35,423	32,132
Sales and marketing	9,186	6,978	17,026	13,401
General and administrative	18,203	18,539	34,331	34,444
Total operating expenses	46,730	42,664	86,780	79,977
Loss from operations	(20,045)	(26,822)	(39,257)	(50,652)
Other income (expense):				
Interest income	2,116	2,620	4,444	4,325
Other income (expense), net	(60)	(26)	(89)	277
Total other income, net	2,056	2,594	4,355	4,602
Loss before income taxes	(17,989)	(24,228)	(34,902)	(46,050)
Provision for (benefit from) income tax expense	125	(3,616)	677	(3,421)
Net loss	\$ (18,114)	\$ (20,612)	\$ (35,579)	\$ (42,629)
Other comprehensive income (loss)				
Changes in unrealized gain (loss) on available for sale securities	(171)	(70)	(291)	(24)
Foreign currency translation adjustments	—	401	—	481
Total comprehensive loss	\$ (18,285)	\$ (20,281)	\$ (35,870)	\$ (42,172)
Net loss per common share, basic and diluted	\$ (0.27)	\$ (0.38)	\$ (0.56)	\$ (0.80)
Weighted-average shares used to compute basic and diluted net loss per share	65,990,437	54,466,143	63,587,322	53,482,635

The accompanying notes are an integral part of these condensed consolidated financial statements

OUSTER, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(unaudited)
(in thousands, except share data)

	Common Stock		Additional	Accumulated	Accumulated other	Total
	Shares	Amount	Paid-in-Capital	Deficit	comprehensive income (loss)	Stockholders' Equity
Balance — December 31, 2025	60,947,757	48	\$ 1,235,580	\$ (973,448)	\$ (442)	\$ 261,738
Issuance of common stock upon exercise of stock options	44,548	—	94	—	—	94
Issuance of common stock in connection with Stereolabs acquisition	1,847,677	—	22,779	—	—	22,779
Issuance of common stock upon vesting of restricted stock units	621,109	—	—	—	—	—
Common stock warrants issuable to customer	—	—	1,101	—	—	1,101
Stock-based compensation expense	—	—	7,494	—	—	7,494
Net loss	—	—	—	(17,465)	—	(17,465)
Other comprehensive loss	—	—	—	—	(120)	(120)
Balance — March 31, 2026	63,461,091	48	1,267,048	(990,913)	(562)	275,621
Issuance of common stock upon exercise of stock options	399,267	—	2,248	—	—	2,248
Proceeds from at-the-market offering, net of commissions and fees of \$2,002 and issuance costs of \$252	3,649,000	—	97,733	—	—	97,733
Issuance of common stock upon vesting of restricted stock units	882,009	—	—	—	—	—
Issuance of common stock to employees under employee stock purchase plan	98,430	—	1,332	—	—	1,332
Common stock warrants issuable to customer	—	—	1,274	—	—	1,274
Stock-based compensation expense	—	—	11,385	—	—	11,385
Net loss	—	—	—	(18,114)	—	(18,114)
Other comprehensive loss	—	—	—	—	(171)	(171)
Balance — June 30, 2026	68,489,797	\$ 48	\$ 1,381,020	\$ (1,009,027)	\$ (733)	\$ 371,308

	Common Stock		Additional	Accumulated	Accumulated other	Total
	Shares	Amount	Paid-in-Capital	Deficit	comprehensive income (loss)	Stockholders' Equity
Balance — December 31, 2024	52,560,770	\$ 47	\$ 1,094,938	\$ (913,071)	\$ (1,003)	\$ 180,911
Issuance of common stock upon exercise of stock options	13,558	—	28	—	—	28
Issuance of common stock in connection with Velodyne Merger	164,394	—	—	—	—	—
Issuance of common stock upon vesting of restricted stock units	1,118,320	—	—	—	—	—
Forfeited restricted stock awards	(68,072)	—	—	—	—	—
Common stock warrants issuable to customer	—	—	397	—	—	397
Stock-based compensation expense	—	—	8,498	—	—	8,498
Net loss	—	—	—	(22,017)	—	(22,017)
Other comprehensive income	—	—	—	—	126	126
Balance — March 31, 2025	53,788,970	47	1,103,861	(935,088)	(877)	167,943
Issuance of common stock upon exercise of stock options	12,497	—	20	—	—	20
Proceeds from at-the-market offering, net of commissions and fees of \$1,200 and issuance costs of \$277	3,522,177	—	58,521	—	—	58,521
Issuance of common stock upon vesting of restricted stock units	275,125	—	—	—	—	—
Issuance of common stock to employees under employee stock purchase plan	201,534	—	980	—	—	980
Common stock warrants issuable to customer	—	—	624	—	—	624
Stock-based compensation expense	—	—	13,226	—	—	13,226
Net loss	—	—	—	(20,612)	—	(20,612)
Other comprehensive income	—	—	—	—	331	331
Balance — June 30, 2025	57,800,303	\$ 47	\$ 1,177,232	\$ (955,700)	\$ (546)	\$ 221,033

The accompanying notes are an integral part of these condensed consolidated financial statements

OUSTER, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)

	Six Months Ended June 30,	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$ (35,579)	\$ (42,629)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	5,936	3,654
Loss on write-off and disposal of property and equipment	—	85
Gain on lease termination	—	(65)
Stock-based compensation	18,879	21,724
Deferred taxes	(571)	—
Reduction of revenue related to stock warrant issued to customer	2,375	1,021
Amortization of right-of-use asset	1,663	2,509
Accretion on short-term investments	(1,115)	(1,488)
Change in fair value of warrant liabilities	—	229
(Recovery) provision for inventory write-down	(52)	465
(Recovery) provision for doubtful accounts	(86)	137
Realized gain on sale of available for sale securities	(14)	(4)
Changes in operating assets and liabilities, net of effects of business acquisition:		
Accounts receivable	10,643	6,471
Inventory	(5,652)	2,049
Prepaid expenses and other assets	(9,868)	(3,640)
Accounts payable	841	6,425
Accrued and other liabilities	44	3,978
Contract liabilities	(5,600)	(3,836)
Operating lease liability	(1,883)	(3,273)
Net cash used in operating activities	(20,039)	(6,188)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of property and equipment	(5,209)	(1,441)
Purchase of short-term investments	(122,307)	(79,686)
Proceeds from sales and maturities of short-term investments	94,995	57,250
Acquisition of Stereolabs, net of cash acquired	(27,493)	—
Net cash used in investing activities	(60,014)	(23,877)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from ESPP purchase	1,332	980
Proceeds from exercise of stock options	2,342	48
Payments received to fund employees tax obligation for vested RSUs	1,629	357
Proceeds from the issuance of common stock under at-the-market offering, net of commissions and fees	97,985	58,798
At-the-market offering costs for the issuance of common stock	(20)	(10)
Net cash provided by financing activities	103,268	60,173
Effect of exchange rates on cash and cash equivalents	—	480
Net increase in cash, cash equivalents and restricted cash	23,215	30,588
Cash, cash equivalents and restricted cash at beginning of period	69,980	48,099
Cash, cash equivalents and restricted cash at end of period	\$ 93,195	\$ 78,687

SUPPLEMENTAL DISCLOSURES OF OPERATING ACTIVITIES:

Income tax (refunds) payments, net	\$ (1,640)	\$ 75
------------------------------------	------------	-------

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:

Property and equipment purchases included in accounts payable and accrued liabilities	\$ 432	\$ 743
Right-of-use assets obtained in exchange for operating lease liability	\$ —	\$ 742
Common stock shares issued in the acquisition of Stereolabs	\$ 22,780	\$ —
Unpaid at-the-market offering costs	\$ 232	\$ —

The accompanying notes are an integral part of these condensed consolidated financial statements

OUSTER, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Note 1 – Description of Business and Basis of Presentation

Description of Business

Ouster, Inc. (“Ouster” or the “Company”) was incorporated in the Cayman Islands on June 4, 2020 as “Colonnade Acquisition Corp.” Following the closing of a business combination between the Company and Ouster Technologies, Inc. (formerly, Ouster, Inc.) in March 2021, the Company domesticated as a Delaware corporation and changed its name to “Ouster, Inc.” Ouster is a leader in sensing and perception for Physical Artificial Intelligence (Physical AI). Ouster’s product offerings enable machines to “Sense, Think, Act, and Learn” and independently execute tasks without human intervention. Physical AI allows machines to move beyond fixed, preprogrammed behavior into adaptive, intelligent action by focusing on perception, understanding, and learning from the physical world. Ouster offers a unified sensing and perception platform that combines high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and cutting-edge AI models to our customers.

On February 4, 2026 (“Closing Date”), the Company completed the acquisition of Stereolabs SAS (“Stereolabs”), accounted for as a business combination. See Note 3.

Basis of Presentation and Principles of Consolidation

The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries (all of which are wholly owned) and have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) applicable to interim periods. All intercompany balances and transactions have been eliminated in consolidation. The presentation of certain prior period amounts has been reclassified to conform with current period presentation.

The unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the results of operations for the periods shown. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2025 and the notes related thereto, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2026. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by applicable rules and regulations. The results of operations for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other future years or interim periods.

Liquidity

The Company’s principal sources of liquidity are its cash and cash equivalents, short-term investments, cash generated from sales of the Company’s products, sales of common stock under its at-the-market equity offering program and debt financing.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis. The Company has experienced recurring losses from operations, and negative cash flows from operations. As of June 30, 2026, the Company’s existing sources of liquidity included cash, cash equivalents, restricted cash and short-term investments of \$262.5 million. The Company has incurred losses and negative cash flows from operations since inception. If the Company continues to incur losses in the future, it may need to improve liquidity and raise additional capital through the issuance of equity and/or debt. There can be no assurance that the Company would be able to raise such capital. However, management believes that the Company’s existing sources of liquidity are adequate to fund its operations for at least twelve months from the date the unaudited condensed consolidated financial statements were available for issuance.

Reclassification

Certain amounts within the segment disclosure in the footnote to the condensed consolidated financial statements for the three and six months ended June 30, 2025, have been conformed to the current period presentation.

Note 2 – Summary of Significant Accounting Policies

During the three and six months ended June 30, 2026, except as noted below there were no significant changes to the Company’s significant accounting policies as disclosed in the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2026. The Company has consistently applied the accounting policies to all periods presented in these unaudited condensed consolidated financial statements.

Foreign Currencies

On January 1, 2026, the Company reassessed the functional currency of its foreign subsidiaries and determined it was the U.S. Dollar for all its subsidiaries. The impact of this change was not material. Foreign currency transaction gains and losses are recorded in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.

Tariff Refunds

On February 20, 2026, the U.S. Supreme Court issued a ruling striking down tariffs imposed under the International Emergency Economic Powers Act ("IEEPA"). On April 20, 2026, the U.S. Customs and Border Protection ("CBP") launched a system to process refund claims for certain invalidated IEEPA tariffs. During the quarter ended June 30, 2026, we submitted our claim for a refund of the IEEPA tariffs through the CBP portal established to process such claims. In accordance with Accounting Standards Codification 450-30, "Gain Contingencies," the Company has elected to use a gain contingency model to account for recoveries of previously paid IEEPA tariffs. Under this model, a gain contingency is not recognized until the gain is realized or realizable. The tariffs at issue were previously capitalized to inventory and subsequently expensed through cost of goods sold. Accordingly, any refund represents a recovery of previously recognized costs, and recognition is limited to amounts previously recorded.

During the second quarter of fiscal 2026, the Company's refund claims were formally accepted by CBP, at which point management concluded the gain was realized or realizable under its elected accounting policy. The Company recognized a benefit of \$5.4 million in cost of sales within the unaudited condensed consolidated statements of operations and comprehensive loss for the recovery of certain IEEPA import duties previously paid. As of June 30, 2026, the Company received \$0.6 million and recorded \$4.8 million of outstanding IEEPA import duty receivables plus interest reflected within prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets (see Note 5). Subsequent to June 30, 2026, the Company received \$4.8 million of outstanding IEEPA import duty receivables plus interest.

Government Credits

The employee retention credit ("ERC"), as originally enacted through the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") on March 27, 2020, is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The Disaster Tax Relief Act, enacted on December 27, 2020, extended the ERC for qualified wages paid from January 1, 2021 to June 30, 2021 and the credit was increased to 70% of qualified wages an eligible employer pays to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the employee retention credit through December 31, 2021. The Company qualified for the ERC for the period between March 17, 2020 and September 30, 2021. The Company recognizes government credits for which there is a reasonable assurance of compliance with credit conditions and receipt of credits. In the quarter ended June 30, 2025, the Company received a credit in the amount of \$5.4 million, which was recorded as follows: \$1.7 million as a reduction in cost of revenue, \$2.2 million as a reduction in research and development expense, \$0.7 million as a reduction in sales and marketing expense and \$0.8 million as a reduction to general and administrative expense in the condensed consolidated statement of operations for the three and six months ended June 30, 2025. The qualified wages and health insurance benefits paid by the Company were related to the first and second quarters of 2021.

Recently Issued and Adopted Accounting Pronouncements

In July 2025, the FASB issued Accounting Standards Update ("ASU") 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets ("ASU 2025-05"). This standard introduces a practical expedient that companies can choose to apply when determining allowances for credit losses. Specifically, it permits companies to assume that the current conditions as of the balance sheet date remain unchanged throughout the remaining life of the assets. Effective January 1, 2026, the Company adopted the amendments in this update for the annual period beginning fiscal year 2026 and applied the new requirements prospectively to the current annual period. The implementation of ASU 2025-05 did not have a material impact on the condensed consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

The Company considers the applicability and impact of all ASUs. ASUs not referenced below were assessed and determined to be not applicable and are not expected to have a material impact on the Company's consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, "Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40) Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06)", which is intended to simplify the capitalization guidance for internal-use software by removing references to project stages and clarifying when the capitalizing of eligible costs is required. The new guidance is effective for annual periods beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. ASU 2025-06 may be applied retrospectively or prospectively.

The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements and related disclosures.

In May 2025, the FASB issued ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810) ("ASU 2025-03"), which clarifies the requirements for determining the accounting acquirer in the acquisition of a variable interest entity. ASU 2025-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. The amendments in this update require that an entity apply the new guidance prospectively to any acquisition transaction that occurs after the initial application date. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the disclosure impact that ASU 2025-03 may have on its financial statement presentation and disclosures.

In May 2025, the FASB issued ASU 2025-04, Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) ("ASU 2025-04"), which clarifies the requirements for share-based consideration payable to a customer. The amendments in this update are effective for all entities for annual reporting periods (including interim reporting periods within annual reporting periods) beginning after December 15, 2026. Early adoption is permitted for all entities. The Company is currently evaluating the disclosure impact that ASU 2025-04 may have on its financial statement presentation and disclosures.

In November 2024, the FASB issued ASU 2024-03, "Disaggregation of Income Statement Expenses." The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures. The guidance is effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The guidance is to be applied prospectively, with the option for retrospective application. The Company is currently evaluating the impact of the ASU on the disclosures within the consolidated financial statements.

Concentrations of Credit Risk

Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, short-term investments and accounts receivable. Although the Company deposits its cash, cash equivalents, restricted cash and short-term investments with financial institutions that Company believes are of high credit quality, its deposits, at times, may exceed federally insured limits. As of June 30, 2026 and December 31, 2025, the Company had cash, cash equivalents, short-term investments and restricted cash with financial institutions in the U.S. of \$242.8 million and \$201.3 million, respectively. As of June 30, 2026 and December 31, 2025, the Company also had cash with financial institutions in countries other than the U.S. of approximately \$19.7 million and \$9.9 million, respectively, that was not federally insured.

The Company generally does not require collateral or other security deposits for accounts receivable.

To reduce credit risk, the Company considers customer creditworthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms when determining the collectability of specific customer accounts. Past due balances over 90 days and other higher risk amounts are reviewed individually for collectability. Based on management's assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

Accounts receivable from the Company's major customers representing 10% or more of total accounts receivable and unbilled receivable was as follows:

	June 30, 2026	December 31, 2025
Customer A	30 %	42 %
Customer B	*	14 %
Customer D	— %	13 %
Customer E	26 %	*

*Customer accounted for less than 10% of total accounts receivable in the period.

Revenue from the Company's major customers representing 10% or more of total revenue was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Customer D	*	11 %	*	*
Customer E	32 %	23 %	31 %	19 %
Customer F	12 %	*	*	11 %
Customer G	*	14 %	*	*

*Customer accounted for less than 10% of total revenue in the period.

Concentrations of Supplier Risk

Purchases from the Company's suppliers and vendors representing 10% or more of total purchases were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Supplier A	*	10 %	*	11 %
Supplier B	31 %	22 %	30 %	24 %

*Supplier accounted for less than 10% of total purchases in the period.

Accounts payable to the Company's major suppliers and professional services vendors representing 10% or more of total accounts payable were as follows:

	June 30, 2026	December 31, 2025
Supplier A	*	13 %
Supplier B	56 %	50 %
Supplier C	*	10 %

*Supplier accounted for less than 10% of total accounts payable.

Note 3. Business Combination and Related Transactions

On the Closing Date, the Company acquired 100% of the outstanding share capital of Stereolabs, a privately-held developer, manufacturer and seller of vision systems headquartered in France. The acquisition expanded the Company's product portfolio, and is expected to further strengthen its software capabilities and accelerate customer development.

Shareholders of Stereolabs received cash consideration of \$32.4 million and 1,847,677 newly issued shares of the Company's common stock, of which 660,005 shares are subject to a staggered lock-up arrangement lasting through a four-year period, whereby twenty-five (25%) percent will be released upon each anniversary of the completion date contingent upon employees remaining employed by the Company. See Note 9.

The consideration paid was comprised of cash and common stock, as follows (in thousands):

Consideration:	
Cash consideration	\$ 32,392
Fair value of common stock issued, less shares subject to continued employment requirements ⁽¹⁾	22,780
	<u>\$ 55,172</u>

⁽¹⁾Calculated based upon 1,187,672 shares at the stock price of \$19.18 per share on the Closing Date.

The Company accounted for the acquisition of Stereolabs as a business combination under ASC 805. This accounting treatment requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. In accordance with ASC 805, the total purchase price was allocated to identifiable tangible and intangible assets acquired and liabilities assumed based on their respective estimated fair values using management's best estimates and assumptions to assign fair value.

as of the acquisition date. The allocation of the purchase price to the assets acquired and liabilities assumed is subject to further adjustment within the measurement period which extends up to one year from the acquisition date.

The Company incurred \$5.0 million in acquisition costs for Stereolabs, of which \$3.9 million was incurred in the year ended December 31, 2025, and \$1.2 million was incurred in the six months ended June 30, 2026. These costs were expensed as incurred. Acquisition-related costs are presented within general and administrative expenses in the Company's condensed consolidated statement of operations. In addition, the sellers incurred transaction costs of \$3.0 million which were paid by the Company on the Closing Date.

The following table provides the assets acquired and liabilities assumed as of the date of acquisition (in thousands):

	Estimated Fair Value
Purchase consideration	\$ 55,172
Amounts of identifiable assets and liabilities assumed	
Cash and cash equivalents	\$ 4,899
Accounts receivable, net	1,594
Inventory	2,159
Prepaid expenses and other current assets ⁽¹⁾	4,065
Property and equipment, net	701
Operating lease, right-of-use assets	1,233
Intangible assets, net	23,400
Other non-current assets	66
Accounts payable	(1,692)
Accrued and other current liabilities	(10,792)
Contract liabilities, current	(2,279)
Operating lease liability, current portion	(197)
Operating lease liability, non-current portion	(1,003)
Deferred tax liability	(5,507)
Total identifiable net assets	\$ 16,647
Goodwill	38,525
	\$ 55,172

⁽¹⁾ Prepaid expenses and other current assets includes a \$1.9 million indemnification asset, with the underlying indemnified liability of \$6.3 million recorded within accrued and other current liabilities.

Identified intangible assets acquired and their estimated useful lives as of February 4, 2026, were (in thousands, except years):

	Estimated Useful Life (in years)	Estimated Fair Value
Trade name	6	\$ 1,500
Developed technology	4	14,000
Customer relationships	8	7,900
Intangible assets, net		\$ 23,400

Developed technology relates to Stereolabs' vision-based perception and Artificial Intelligence ("AI") platform that provides real-time depth sensing, 3D mapping, and object detection in complex real-world environments. The Company valued the developed technology using the relief-from-royalty method under the income approach, which involved assumptions related to the economic life, obsolescence curve, and discount rate. The economic life was determined based on the development cycle, benchmarking analysis, and the projected cash flows over the forecasted period.

The estimated fair value of the trade name was determined using the relief-from-royalty method under the income approach, which involved assumptions related to the economic life and discount rate. The Stereolabs trade name is expected to be in use for the foreseeable future and the economic life was determined based on the branding strategy, benchmarking analysis, and the projected cash flows over the forecasted period.

The Company valued the customer relationship intangible asset using the multi-period excess earnings method under the income approach, which involved assumptions related to the economic life and discount rate. The economic life was determined based on expected attrition and existing customer revenue growth, as well as the period over which the majority of discounted cash flows would be realized.

The excess of the purchase consideration and the fair value of identifiable assets acquired and liabilities assumed at the acquisition date over the fair value of net tangible and identified intangible assets acquired was recorded as goodwill, which is deductible for tax purposes. Goodwill is primarily attributable to the assembled workforce and the anticipated operational synergies expected from the Stereolabs acquisition.

Approximately \$1.9 million of the cash consideration is held in an escrow account to cover estimated claims arising from pre-closing tax accruals related to certain historical foreign sales transactions and other taxes (“the Specific Tax Loss”). Any remaining portion of the escrow amount that is not required to cover the Specific Tax Loss amounts will be paid to the former shareholders of Stereolabs at December 31, 2027 (the escrow release date). The indemnification of the Specific Tax Loss is capped at \$1.9 million, the amount of the escrow fund balance. At the acquisition date, the associated Specific Tax Loss was recorded at the estimated fair value of \$6.3 million within accrued and other current liabilities and the Company recorded an indemnification asset up to the amount of the escrow fund balance of \$1.9 million.

The unaudited supplemental pro forma information below presents the combined historical results of operations of the Company and Stereolabs as if Stereolabs had been acquired as of January 1, 2025 (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Revenue	\$ 54,626	\$ 37,900	\$ 105,189	\$ 73,831
Net loss	\$ (18,114)	\$ (22,663)	\$ (42,359)	\$ (54,511)

The unaudited supplemental pro forma information above includes the following adjustments to net loss in the appropriate pro forma periods (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
An increase in amortization expense related to the fair value of acquired identifiable intangible assets, net of the amortization expense already reflected in actual historical results.	\$ —	\$ (1,184)	\$ (484)	\$ (2,368)
A decrease (increase) in expenses related to the transaction expenses. This amount includes \$3.0 million in transaction expenses incurred by the sellers.	\$ —	\$ —	\$ 4,137	\$ (8,022)
An increase in additional stock-based compensation expense related to shares issued to key Stereolabs employees in the acquisition that are considered compensatory in the post business combination periods due to the additional service requirement, net of the stock compensation expense already reflected in actual historical results.	\$ —	\$ (780)	\$ (303)	\$ (1,560)
A decrease (increase) in additional stock-based compensation expense related to the impact of the acceleration of Stereolabs warrants that vested at the close of the Stereolabs acquisition.	\$ —	\$ —	\$ 207	\$ (207)

The unaudited supplemental pro forma information has been presented for illustrative purposes only and is not necessarily indicative of results of operations that would have been achieved had the Stereolabs taken place on the date indicated, or of the Company’s future consolidated results of operations. The supplemental pro forma information presented above has been derived from the Company’s historical consolidated financial statements and from historical consolidated financial statements and the historical accounting records of Stereolabs.

Note 4. Fair Value of Financial Instruments

The following tables provides information by level for the Company's assets that were measured at fair value on a recurring basis (in thousands):

	June 30, 2026		
	Level 1	Level 2	Total
Assets			
Cash and cash equivalents:			
Money market funds	\$ 68,769	\$ —	\$ 68,769
Short-term investments:			
Commercial paper	—	97,929	97,929
Corporate debt securities	—	71,393	71,393
Total short-term investments	—	169,322	169,322
Total financial assets	\$ 68,769	\$ 169,322	\$ 238,091
December 31, 2025			
	Level 1	Level 2	Total
	Level 1	Level 2	Total
Assets			
Cash and cash equivalents:			
Money market funds	\$ 54,475	\$ —	\$ 54,475
Short-term investments:			
Commercial paper	—	68,326	68,326
Corporate debt securities	—	72,846	72,846
Total short-term investments	—	141,172	141,172
Total financial assets	\$ 54,475	\$ 141,172	\$ 195,647

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.

The value of securities included in Level 2 are based on other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

The value and changes in Level 3 liabilities measured at fair value on a recurring basis are immaterial.

Non-Recurring Fair Value Measurements

The Company has certain assets, including intangible assets, which are measured at fair value on a non-recurring basis and are adjusted to fair value only if an impairment charge is recognized. The categorization of the framework used to measure fair value of the assets is considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used.

Disclosure of Fair Values

The Company's financial instruments that are not re-measured at fair value include accounts receivable, accounts payable, accrued and other current liabilities. The carrying values of these financial instruments approximate their fair values. Unrealized gains and losses on the Company's short-term investments were not significant as of June 30, 2026 and December 31, 2025, and therefore, the amortized cost of the Company's short-term investments approximated its fair value.

Note 5. Balance Sheet Components

Cash and Cash Equivalents

The Company's cash and cash equivalents consist of the following (in thousands):

	June 30, 2026	December 31, 2025
Cash	\$ 22,990	\$ 12,938
Cash equivalents:		
Money market funds ⁽¹⁾	68,769	54,475
Total cash and cash equivalents	<u>\$ 91,759</u>	<u>\$ 67,413</u>

⁽¹⁾The Company maintains a cash sweep account, which is included in money market funds as of June 30, 2026 and December 31, 2025. Cash is invested in short-term money market funds that earn interest.

Restricted Cash

Restricted cash consists of collateral to merchant credit card, deposit account to secure foreign entity closure costs, issuances of deposit performance guarantee issued in favor of a customer, and certificates of deposit held by a bank as security for outstanding letters of credit. The Company had a restricted cash balance of \$1.4 million and \$2.6 million as of June 30, 2026 and December 31, 2025, respectively, which has been excluded from the Company's cash and cash equivalents balances. The Company presented \$0.3 million and \$1.5 million of the total amount of restricted cash within current assets on the unaudited condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, respectively. The remaining restricted cash balance of \$1.1 million and \$1.1 million is included in non-current assets on the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, respectively.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the unaudited condensed consolidated balance sheets to the total of the amounts reported in the unaudited condensed consolidated statements of cash flows (in thousands):

	June 30, 2026	June 30, 2025
Cash and cash equivalents	\$ 91,759	\$ 76,120
Restricted cash, current	336	732
Restricted cash, non-current	1,100	1,835
Total cash, cash equivalents and restricted cash	<u>\$ 93,195</u>	<u>\$ 78,687</u>

Inventory

Inventory, consisting of material, direct and indirect labor, and manufacturing overhead, consists of the following (in thousands):

	June 30, 2026	December 31, 2025
Raw materials	\$ 11,051	\$ 3,866
Work in process	1,500	93
Finished goods	18,878	19,607
Total inventory	<u>\$ 31,429</u>	<u>\$ 23,566</u>

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):

	June 30, 2026	December 31, 2025
Prepaid expenses	\$ 8,841	\$ 3,529
Prepaid inventory	2,908	2,887
Prepaid insurance	2,132	967
Receivable from contract manufacturer	5,248	3,497
Import duty receivable (See Note 2.)	4,930	—
IRS Income tax refund receivable	—	2,993
Indemnification asset (See Note 3.)	1,855	—
Other current assets	4,829	3,644
Total prepaid expenses and other current assets	<u>\$ 30,743</u>	<u>\$ 17,517</u>

Property and Equipment, net

Property and equipment consists of the following (in thousands):

	Estimated Useful Life (in years)	June 30, 2026	December 31, 2025
Land	Not depreciated	\$ 7,798	\$ 7,798
Building	25	9,453	9,453
Machinery and equipment	3	20,043	16,640
Computer equipment	3	1,816	1,140
Automotive and vehicle hardware	5	93	93
Software	3	438	160
Furniture and fixtures	7	1,129	863
Construction in progress		8,144	7,326
Leasehold improvements	Shorter of useful life or lease term	5,134	5,097
		54,048	48,570
Less: Accumulated depreciation		(18,807)	(16,679)
Property and equipment, net		<u>\$ 35,241</u>	<u>\$ 31,891</u>

Depreciation expense associated with property and equipment was \$2.1 million and \$1.4 million during the six months ended June 30, 2026 and 2025, respectively.

Goodwill and Acquired Intangible Assets, Net

The changes in the carrying amount of goodwill are as follows (in thousands):

	Amount
Balance at December 31, 2025	\$ —
Goodwill addition related to Stereolabs acquisition	38,525
Balance at June 30, 2026	<u>\$ 38,525</u>

Annually, and/or upon the identification of a triggering event, management is required to perform an assessment of fair value relative to carrying value of goodwill. Triggering events potentially warranting an interim goodwill impairment test include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained declines in the Company's stock price or market capitalization, considered both in absolute terms and relative to peers. There were no triggering events during the three and six months ended June 30, 2026.

The following tables present acquired intangible assets, net as of June 30, 2026 and December 31, 2025 (in thousands):

	Estimated Useful Life (in years)	June 30, 2026		
		Gross Carrying Amount	Accumulated Amortization	Net Book Value
Trade name	6	\$ 1,500	\$ (99)	\$ 1,401
Developed technology	3-8	37,500	(16,617)	20,883
Vendor relationship	3	6,600	(6,600)	—
Customer relationships	3 - 8	14,200	(3,576)	10,624
Intangible assets, net		<u>\$ 59,800</u>	<u>\$ (26,892)</u>	<u>\$ 32,908</u>

	Estimated Useful Life (in years)	December 31, 2025		
		Gross Carrying Amount	Accumulated Amortization	Net Book Value
Developed technology	3-8	\$ 23,500	\$ (13,634)	\$ 9,866
Vendor relationship	3	6,600	(6,600)	—
Customer relationships	3-8	6,300	(2,850)	3,450
Intangible assets, net		<u>\$ 36,400</u>	<u>\$ (23,084)</u>	<u>\$ 13,316</u>

Amortization expense was \$3.8 million and \$2.2 million during the six months ended June 30, 2026 and 2025, respectively.

The following table summarizes estimated future amortization expense of finite-lived intangible assets-net (in thousands):

Years:	Amount
Remainder of 2026	\$ 4,234
2027	8,416
2028	7,526
2029	7,065
2030	2,257
Thereafter	3,410
Total	<u>\$ 32,908</u>

Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in thousands):

	June 30, 2026	December 31, 2025
Accrued legal fees and contingencies	\$ 2,182	\$ 2,124
Uninvoiced receipts	12,751	7,910
Accrued compensation	9,304	7,415
Warranty reserve	1,957	1,800
Sales, use, value-added taxes, customs duties and other taxes ⁽¹⁾	9,325	3,108
Other	3,240	3,843
Total accrued and other current liabilities	<u>\$ 38,759</u>	<u>\$ 26,200</u>

⁽¹⁾ Includes indemnified Specific Tax Loss Liabilities of \$6.3 million from the Stereolabs acquisition. The indemnification of the Specific Tax Loss is capped at \$1.9 million. See Note 3.

Note 6. Amazon Warrant

On February 10, 2023, as part of the Velodyne Merger, the Company assumed a warrant agreement and a transaction agreement, pursuant to which Velodyne agreed to issue to Amazon.com NV Investment Holdings LLC, a wholly-owned subsidiary of Amazon.com Inc. (“Amazon”), a warrant to acquire, following customary antidilution adjustments, up to an aggregate of 3,263,898 shares of the Company’s common stock at an exercise price of \$50.71 per share (the “Amazon Warrant”). The exercise price and the warrant shares issuable upon exercise of the Amazon Warrant are subject to further antidilution adjustments, including in the event the Company makes certain sales of common stock (or securities exercisable or convertible into or exchangeable for shares of the Company’s common stock) at a price less than the exercise price of the Amazon Warrant. During the six months ended June 30, 2026, the Company issued an additional 1,847,677 shares of common stock pursuant to the Stereolabs acquisition at effective prices below the exercise price of the Amazon Warrant, resulting in an antidilution adjustment to the terms of the Amazon Warrant with an increase in the number of shares issuable under the Amazon Warrant by 5,185 shares of common stock and a reduction to the original strike price of the Amazon Warrant to \$50.49 per share.

As a result of the issuance and sale by the Company of an additional 3,649,000 shares of common stock in the three months ended June 30, 2026 pursuant to a Sales Agreement (the “ATM Agreement”), dated May 8, 2026, by and among the Company, Oppenheimer & Co. Inc., Northland Securities, Inc., Rosenblatt Securities Inc., and Roth Capital Partners, LLC, at prices below the exercise price of the Amazon Warrant, an antidilution adjustment to the terms of the Amazon Warrant occurred (see Note 8), resulting in the increase in the number of shares issuable under the Amazon Warrant by 12,939 shares of common stock and a reduction to the original strike price of the Amazon Warrant to \$50.30 per share.

As of June 30, 2026, there were 3,290,094 shares of common stock issuable under the Amazon Warrant.

The Amazon Warrant shares vest in multiple tranches over time based on payments of up to \$100.0 million by Amazon or its affiliates (directly or indirectly through third parties) to the Company in connection with Amazon’s purchase of goods and services. The fair value of the unvested Amazon Warrant will be recognized as a non-cash stock-based reduction to revenue when Amazon makes payments and vesting conditions become probable of being achieved.

The fair value of the Amazon Warrant shares was estimated on February 10, 2023, the date of completion of the Velodyne Merger, using the Black-Scholes option pricing model on the remaining contractual term of 6.98 years, an expected volatility of 53.7%, a 3.86% risk-free interest rate and a 0% expected dividend yield.

The right to exercise the Amazon Warrant and receive the warrant shares that have vested expires February 4, 2030.

In the three months ended June 30, 2026, 289,490 Amazon Warrant shares vested. In the six months ended June 30, 2026, 432,380 Amazon Warrant shares vested. As of June 30, 2026, there were 3,161,365 Amazon Warrant shares vested.

Note 7. Commitments and Contingencies***Letters of Credit***

In connection with certain office leasehold interests in real property located in San Francisco (350 Treat Ave. and 2741 16th Street), the Company obtained letters of credit from certain banks as required by the lease agreements. If the Company defaults under the terms of the applicable lease, the lessor will be entitled to draw upon the letters of credit in the amount necessary to cure the default. The amounts covered by the letters of credit are collateralized by certificates of deposit, which are included in restricted cash on the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025. The amount collateralizing the 2741 16th Street lease letter of credit following the purchase of the property and the termination of the 2741 16th Street lease was released during the first fiscal quarter of 2026. The outstanding amount of the letters of credit was \$0.3 million and \$1.4 million as of June 30, 2026 and December 31, 2025, respectively.

Non-cancelable purchase commitments

As of June 30, 2026, the Company had non-cancelable purchase commitments to third-party contract manufacturers for approximately \$24.8 million and other vendors for approximately \$21.5 million.

Contingencies

From time to time, the Company may be involved in legal and administrative proceedings arising in the ordinary course of business. The Company records a liability in its consolidated financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. If a loss is probable but the amount of loss cannot be reasonably estimated, the Company discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made). Legal costs incurred in connection with loss contingencies are expensed as incurred.

Litigation

The Company is involved in various legal proceedings arising in the ordinary course of business. Significant judgment is required in both the determination of probability and the determination as to whether any exposure is reasonably estimable. Actual outcomes of these legal and regulatory proceedings may materially differ from our current estimates.

Velodyne Legacy Litigation

In 2022, David and Marta Hall filed a lawsuit against current and former officers and directors of Velodyne, which proceeded through arbitration. In addition, in 2023, David and Marta Hall filed a separate complaint against Velodyne seeking indemnification for legal fees in California state court. The parties agreed to a confidential settlement, without any admission or concession of wrongdoing or liability, for both matters and executed the definitive agreement on April 16, 2025. The Company paid an immaterial amount in settlement expenses in the second quarter of fiscal 2025. An insurance receivable allowed the Company to recover the majority of the settlement expenses, resulting in a net charge that was immaterial to its consolidated statement of operations.

In 2023, a putative shareholder class action suit was filed in Delaware against former officers and directors of Graf Acquisition LLC (Velodyne was not named as a defendant in *Berger v. Graf Acquisition, LLC*, No. C.A.2023-0873-LWW (Del. Ch.)). The parties agreed to a settlement without any admission or concession of wrongdoing or liability. The Company paid an immaterial amount in settlement expenses in the third quarter of fiscal 2025. An insurance receivable allowed the Company to recover the majority of the expected settlement expenses, resulting in a net charge that was immaterial to its consolidated statement of operations. The court approved the settlement and entered final judgment on October 8, 2025.

Ouster Litigation

On April 11, 2023, the Company filed a complaint in the District of Delaware alleging patent infringement of certain claims of the Company's U.S. Patent Nos. 11,175,405, 11,178,381, 11,190,750, 11,287,515, and/or 11,422,236 against Hesai Group and Hesai Technology Co., Ltd. Subject to the terms of a confidential decision in the arbitration described below, the Company dismissed without prejudice this case on April 11, 2025.

On May 17, 2023, Hesai Photonics Technology Co. Ltd. and Hesai Group (collectively "Hesai Photonics") filed a request for arbitration with JAMS against the Company, Velodyne Lidar, Inc., Velodyne, LLC, and Oban Merger Sub II LLC. Hesai Photonics alleges that the Company is bound as a result of the Company's 2023 merger with Velodyne Lidar, Inc. by the terms and conditions, including an obligation to arbitrate disputes, of a long-term, global cross-licensing settlement agreement signed in 2020 between Hesai Photonics and Velodyne Lidar, Inc. ("Velodyne-Hesai Settlement Agreement"). On June 13, 2023, the Company responded to the arbitration demand and denied all allegations. On March 28, 2025, the tribunal issued a confidential interim decision, finding that the Company was subject to the Velodyne-Hesai Photonics Settlement Agreement. On September 15, 2025, the tribunal issued a confidential final decision, affirming the earlier finding of a global licensing settlement agreement that requires Hesai Photonics to pay royalties and deciding on fees in the amount of approximately \$6.4 million, which the Company paid in the fourth quarter of fiscal 2025.

On September 14, September 25, and September 26, 2023, Hesai filed Petitions for Inter Partes Review with the Patent Trial and Appeal Board (“PTAB”) challenging the validity of the Company’s patents asserted in the ITC and Delaware patent actions. The Company provided preliminary responses to those petitions in late December 2023 and early January 2024. On March 19, 2024, March 28, 2024, and April 1, 2024, the PTAB issued decisions to institute inter partes review for four patents: IPR2023-01421 (Patent No. 11,175,405), hearing date of December 17, 2024; IPR2023-01422 (Patent No. 11,287,515), hearing date of December 17, 2024; IPR2023-01456 (Patent No. 11,178,381), hearing date of January 13, 2025; and IPR2023-01457 (Patent No. 11,190,750), hearing date of January 13, 2025. On March 13, 2025, the PTAB issued final written decisions upholding the patentability of all challenged claims in IPR2023-01422, and finding unpatentable all challenged claims in IPR2023-01421 and IPR2023-01457. On March 17, 2025, the PTAB issued a final written decision finding unpatentable all challenged claims of IPR2023-01456. On June 2 and 3, 2025, the Company filed notices of appeal for IPR2023-01421, IPR 2023-01426, and IPR 2023-01457, but the parties dismissed all but IPR2023-01421, which is awaiting hearing. Regarding the fifth patent (Patent No. 11,422,236), the PTAB declined to institute on March 28, 2024, (see IPR2023-01458). Hesai requested review to the Director of the United States Patent and Trademark Office (“Director Review”), who remanded to the PTAB for further review of its decision not to institute. On January 21, 2025, the PTAB again denied institution, to which Hesai again requested Director Review, and the Company objected. On March 20, 2025, the Director again denied review.

Indemnification

From time to time, the Company enters into agreements in the ordinary course of business that include indemnification provisions. Generally, in these provisions the Company agrees to defend, indemnify, and hold harmless the indemnified parties for claims and losses suffered or incurred by such indemnified parties for which the Company is responsible under the applicable indemnification provisions. The terms of the indemnification provisions vary depending upon negotiations between the Company and its counterpart; however, typically, these indemnification obligations survive the term of the contract and the maximum potential amount of future payments the Company could be required to make pursuant to these provisions are uncapped.

The Company has also entered into indemnity agreements pursuant to which it has indemnified its directors and officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer, other than liabilities arising from willful misconduct of the individual. To date, the Company is indemnifying and has incurred costs to defend lawsuits or settle claims described above under the heading “Litigation” pursuant to the indemnity agreements of former directors and officers.

Note 8. Common Stock

Pursuant to the terms of our Certificate of Incorporation (as amended, the “Certificate of Incorporation”), the Company is authorized to issue the following shares and classes of capital stock, each with a par value of \$0.0001 per share: (i) 200,000,000 shares of common stock; (ii) 100,000,000 shares of preferred stock. The holder of each share of common stock is entitled to one vote.

On June 17, 2026, the Company's stockholders approved an amendment to our Certificate of Incorporation to increase our number of authorized shares of common stock from 100,000,000 to 200,000,000, and the Company filed a Certificate of Amendment to its Certificate of Incorporation to effect this amendment on the same date.

On May 12, 2025, the Company entered into an At-Market-Issuance Sales Agreement (the “Former ATM Agreement”) with Oppenheimer & Co. Inc., pursuant to which the Company could offer and sell shares of the Company’s common stock, having an aggregate offering price of up to \$100.0 million.

The Company terminated the Former ATM Agreement in May 2026.

From the date of the Former ATM Agreement to its termination, the Company sold 4,671,406 shares at a weighted-average sales price of \$20.88 per share, resulting in cumulative gross proceeds to the Company totaling approximately \$97.5 million before deducting offering costs, sales commissions and fees. Cumulative net proceeds to the Company totaled approximately \$95.6 million after deducting offering costs, sales commissions and fees.

On May 8, 2026, the Company entered into the ATM Agreement with Oppenheimer & Co. Inc., Northland Securities, Inc., Rosenblatt Securities Inc., and Roth Capital Partners, LLC (each, an “Agent” and, collectively the “Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Agents, acting as agent or principal, shares of the Company’s common stock, having an aggregate offering price of up to \$100.0 million.

During the three months ended June 30, 2026, 3,649,000 shares of common stock were sold under the ATM Agreement at a weighted-average sales price of \$27.40 per share, resulting in cumulative gross proceeds to the Company totaling approximately \$100.0 million before deducting offering costs, sales commissions and fees. Cumulative net proceeds to the Company totaled approximately \$98.0 million after deducting offering costs, sales commissions and fees. We plan to use the net proceeds from this offering for working capital and general corporate purposes. As of June 30, 2026, the ATM offering is complete and there are no remaining funds available under the ATM Agreement.

On November 9, 2025, the Company agreed to issue shares of common stock for the acquisition of Stereolabs. See Note 3. Upon the closing of the Stereolabs transaction on February 4, 2026, the Company issued 1,847,677 shares, inclusive of 660,005 shares which will be released over a four-year period. The Company sold the foregoing securities in transactions not involving an underwriter and not requiring registration under Section 5 of the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions afforded by Section 4(a)(2) and/or Regulation S of the Securities Act and the rules and regulations promulgated thereunder.

On July 6, 2026, the Company completed the sale and issuance of an aggregate of 3,621,876 shares of the Company’s common stock. The Company received net proceeds of approximately \$191.9 million, after deducting the underwriter’s discounts and commissions. (See Note 14.)

Note 9. Stock-based Compensation

As of June 30, 2026, the Company maintains five equity incentive plans: its Amended and Restated 2015 Stock Plan (the “2015 Plan”), the Sense Photonics, Inc. 2017 Equity Incentive Plan (the “Sense Plan”), the Velodyne Lidar, Inc. 2020 Equity Incentive Plan (the “Velodyne Plan”), its 2021 Incentive Award Plan (the “2021 Plan”) and its Amended and Restated 2022 Employee Stock Purchase Plan (the “2022 ESPP” and, collectively with the 2015 Plan, the Sense Plan, the Velodyne Plan and the 2021 Plan, the “Plans”).

The Plans, other than the 2022 ESPP, provide for the grant of stock options, stock appreciation rights, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock unit awards and other forms of equity compensation (collectively, “equity awards”). In addition, the 2021 Plan provides for the grant of performance bonus awards. New equity awards may only be granted under the 2021 Plan and Velodyne Plan. Awards under the 2021 Plan and Velodyne Plan can be granted to employees, including officers, directors and consultants of the Company and its subsidiaries, in each case, within the limits provided in the 2021 Plan and Velodyne Plan, respectively.

The Company’s 2022 ESPP has been offered to all eligible employees since August 2022 and generally permits certain employees to purchase shares of our common stock at a discount through payroll deductions of up to 15% of their compensation during each offering period, subject to certain limitations.

The 2022 ESPP provides offering periods that have a duration of 24 months in length and are comprised of purchase periods of six months in length. The offering periods are scheduled to start on the first trading day on or after May 16 and November 16 of each year. Under the 2022 ESPP, the purchase price of a share equals 85% of the lesser of the fair market value of a share of common stock on either the first or last day of the applicable offering period or the last day of the applicable purchase period.

During the three and six months ended June 30, 2026, there were 98,430 shares of common stock issued under the 2022 ESPP.

The stock-based compensation expense for the 2022 ESPP is based on the estimated grant date fair value utilizing the Black-Scholes option valuation model of the 2022 ESPP shares and the number of shares that can be purchased as of the grant date, which is recognized as expense on a straight line expense attribution method over the length of an offering period.

Stock Options

Stock option activity for the six months ended June 30, 2026 was as follows:

	Number of Shares Underlying Outstanding Options	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding—December 31, 2025	1,710,622	\$ 7.69	4.72	\$ 24,142
Options exercised	(443,815)	5.28		
Outstanding—June 30, 2026	1,266,807	\$ 8.54	4.22	\$ 68,385
Vested —June 30, 2026	1,266,807	\$ 8.54	4.22	\$ 68,385
Exercisable—June 30, 2026	1,266,807	\$ 8.54	4.22	\$ 68,385

The following table summarizes information about stock options outstanding and exercisable at June 30, 2026.

Exercise Price	Options Outstanding		Options Exercisable
	Options Outstanding	Weighted Average Remaining Contractual Life (Years)	
\$ 1.85	159,294	4.04	159,294
\$ 2.13	461,616	4.25	461,616
\$ 14.22	636,688	4.25	636,688
\$ 52.40	9,209	3.25	9,209
	1,266,807		1,266,807

As of June 30, 2026, there was no remaining unamortized stock-based compensation expense related to unvested stock options.

Restricted Stock Units

A summary of RSU activity for the six months ended June 30, 2026 was as follows:

	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested—December 31, 2025	4,085,075	\$ 12.02
Granted	2,346,589	25.41
Canceled	(136,224)	14.21
Vested	(1,503,118)	12.13
Unvested—June 30, 2026	4,792,322	\$ 18.48

Stock-based compensation expense is recognized on a straight-line basis over the vesting period of each award of RSUs. As of June 30, 2026, total compensation expense related to unvested RSUs granted to employees, but not yet recognized, was \$80.5 million, with a weighted-average remaining vesting period of 2.1 years. RSUs settle into shares of common stock upon vesting.

Stereolabs Acquisition

In connection with the acquisition of Stereolabs (Note 3), several Stereolabs key employees entered into agreements with the Company whereby these key employees are eligible to receive an aggregate of 660,005 shares of common stock subject to their continued employment with the Company. These shares are excluded from the above restricted stock units table. These shares are considered compensatory in the post-business combination periods due to the additional service requirement for these key employees. These shares are subject to a staggered lock-up arrangement lasting through a four-year period, whereby twenty-five (25%) percent will be released upon each anniversary of the completion date as long as the key employees are still employees of the Company. As of June 30, 2026, there were 660,005 unvested shares outstanding with a grant date fair value of \$19.18 per share subject to future service periods. The Company recognized stock-based compensation expense of \$0.8 million during the three months ended June 30, 2026, and stock-based compensation expense of \$1.3 million during the six months

ended June 30, 2026, related to the 660,005 shares. As of June 30, 2026, there is \$11.4 million remaining unamortized compensation expense that will be recognized over a weighted average remaining period of 3.6 years.

Additionally during the six months ended June 30, 2026, the Company recognized \$0.2 million in stock-based compensation expense related to the impact of the acceleration of Stereolabs warrants that vested at the close of the Stereolabs acquisition.

Stock-Based Compensation Expense

The Company recognized stock-based compensation expense for all share-based awards in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Cost of revenue	\$ 1,395	\$ 1,799	\$ 2,221	\$ 2,935
Research and development	4,332	6,303	6,948	10,608
Sales and marketing	1,177	1,733	1,943	2,839
General and administrative	4,481	3,391	7,767	5,342
Total stock-based compensation	\$ 11,385	\$ 13,226	\$ 18,879	\$ 21,724

The following table summarizes stock-based compensation expense by award type (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
RSUs	\$ 10,219	\$ 11,971	\$ 16,668	\$ 19,304
Employee stock purchase plan	377	291	738	631
RSAs	—	964	—	1,789
Stereolabs post-combination compensation expense	789	—	1,473	—
Total stock-based compensation	\$ 11,385	\$ 13,226	\$ 18,879	\$ 21,724

Note 10. Net Loss Per Common Share

The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Numerator:				
Net loss	\$ (18,114)	\$ (20,612)	\$ (35,579)	\$ (42,629)
Denominator:				
Weighted average shares used to compute basic and diluted net loss per share	65,990,437	54,466,143	63,587,322	53,482,635
Net loss per common share—basic and diluted	\$ (0.27)	\$ (0.38)	\$ (0.56)	\$ (0.80)

The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase.

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

	June 30,	
	2026	2025
Options to purchase common stock	1,266,807	1,728,471
Public and private common stock warrants	3,290,094	5,238,506
Restricted Stock Units	4,792,322	5,608,426
Shares issued to Stereolabs employees and subject to vesting	660,005	—
Share purchase rights under the ESPP	184,331	341,692
Unvested RSAs	—	388,626
Total	10,193,559	13,305,721

Note 11. Income Taxes

The Company's income tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items arising in the quarter. The income tax provision for the three and six months ended June 30, 2026 was \$0.1 million and \$0.7 million, respectively. The income tax provision for the six months ended June 30, 2026 includes \$0.9 million of discrete items primarily related to withholding taxes on sales to customers. Discrete items for the three months ended June 30, 2026, were not significant. The income tax benefit for the three and six months ended June 30, 2025 was \$3.6 million and \$3.4 million, respectively. The income tax benefits recorded for the three and six months ended June 30, 2025 primarily related to the resolution of an IRS examination of the Company's 2017 and 2018 tax years offset by income taxes for its foreign operations.

The Company's effective tax rate was (0.7)% and (1.9)% for the three and six months ended June 30, 2026, respectively, and 14.9% and 7.4% for the three and six months ended June 30, 2025. The Company's effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on the deferred tax assets as it is more likely than not that some, or all, of the Company's deferred tax assets will not be realized. We continue to maintain a full valuation allowance against our U.S. Federal, state and certain foreign deferred tax assets, excluding specific balances related to the Stereolabs acquisition.

Note 12. Revenue

The majority of the Company's revenue is recognized at the point in time when the customer obtains control of the respective lidar sensors, cameras and AI compute systems. Revenue recognized over time is immaterial to total revenue recognized for any given period.

Revenue for the three months ended June 30, 2026, includes patent royalty revenues generated from long-term intellectual property ("IP") license agreements primarily in the Asia and Pacific region in the amount of \$1.9 million. Patent royalty revenue for the three months ended June 30, 2025, was not significant. Revenue for the six months ended June 30, 2026 and 2025, respectively, includes patent royalty revenues in the amount of \$2.2 million and \$1.6 million. The Company also expects to record future revenue from these agreements as it satisfies its performance obligations.

The following table presents total revenues by geographic area based on the location products were shipped to and services provided (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Americas	\$ 35,427	\$ 24,548	\$ 68,225	\$ 40,076
Asia and Pacific	12,566	6,096	20,556	18,560
Europe, Middle East and Africa	6,633	4,405	14,423	9,045
Total	\$ 54,626	\$ 35,049	\$ 103,204	\$ 67,681

Countries that accounted for more than 10% of total revenue were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
United States	62 %	69 %	60 %	58 %
Thailand	*	*	*	11 %

*Country accounted for less than 10% of total revenue in the period.

Revenue contract balances

Timing of revenue recognition may differ from the timing of invoicing to customers. An unbilled receivable is recorded in instances when revenue is recognized prior to invoicing, and amounts collected in advance of services being provided are recorded as deferred revenue. Contract assets and liabilities are generated when contractual billing schedules differ from revenue recognition timing.

Unbilled receivables

A receivable for multi-year licensing services is generally recorded upon invoicing. A receivable for multi-year license agreements is recorded upon delivery, whether or not invoiced, to the extent the Company has an unconditional right to receive payment in the future related to those licenses. As of June 30, 2026, the current portion of these unbilled receivables in the amount of \$5.0 million, primarily consisting of unbilled receivables from multi-year license contracts, is included in “Accounts receivable, net” on the unaudited condensed consolidated balance sheet.

Contract Assets

Contract assets arise when revenue is recognized prior to billing customers and payment is contingent upon a future event, other than the passage of time. Contract assets primarily relate to the Company’s rights to consideration under a long-term IP license agreement when the licenses have been transferred to the customers, but payment is conditional on factors other than the passage of time.

Contract Liabilities

Contract liabilities consist of deferred revenue, advanced payments and deposits from customers for goods and services that are yet to be provided. Deferred revenue includes billings in excess of revenue recognized related to product sales, licenses, extended warranty and other services revenue, and is recognized as revenue when the Company performs under the contract. The long-term portion of deferred revenue, mostly related to obligations under license arrangements and extended warranty, is classified as non-current contract liabilities in the Company’s unaudited condensed consolidated balance sheets. Customer advanced payments represent required customer payments in advance of product shipments according to customer’s payment term. Customer advance payments are recognized as revenue when control of the performance obligation is transferred to the customer. Customer deposits represent consideration received from a customer which can be applied to future product or service purchases, or refunded.

Contract assets and liabilities are presented net at the individual contract level in the unaudited condensed consolidated balance sheet and are classified as current or non-current based on the nature of the underlying contractual rights and obligations.

	June 30, 2026	December 31, 2025
Contract assets, current	\$ 1,008	\$ 937
Contract assets, non-current portion	281	281
Total contract assets	<u>\$ 1,289</u>	<u>\$ 1,218</u>
Contract liabilities, current		
Deferred revenues from multi-year licensing agreements	\$ 133	\$ 133
Other contract liabilities	17,033	20,572
Contract liabilities, non-current portion		
Deferred revenues from multi-year licensing agreements	\$ 354	\$ 429
Other contract liabilities	2,970	2,677
Total contract liabilities	<u>\$ 20,490</u>	<u>\$ 23,811</u>

Deferred revenues from multi-year licensing agreements mainly represent minimum royalty payments received from licensees relating to long-term IP license agreements for which the Company has future obligations. Royalties from the IP license agreements are recognized at the later of the period the sales occur or the satisfaction of the performance obligations to which some or all of the royalties have been allocated.

Other contract liabilities primarily relate to a multi-year contract entered in 2023 with a customer to sell the Company's products. During the three and six months ended June 30, 2026, the Company recognized \$6.1 million in revenue associated with this contract from other contract liabilities. As of June 30, 2026, \$6.4 million remained deferred until a future product delivery date.

The following table provides information about contract liabilities (remaining performance obligations) and the significant changes in the balances (in thousands):

	Six Months Ended June 30,	
	2026	2025
Beginning balance	\$ 23,811	\$ 36,889
Net revenue deferred in the period	4,949	5,377
Contract liabilities acquired in the Stereolabs acquisition	2,279	—
Revenue recognized that was included in the contract liability balance at the beginning of the period	(10,549)	(9,214)
Ending balance	<u>\$ 20,490</u>	<u>\$ 33,052</u>

Note 13. Segment

The Company's chief operating decision maker ("CODM") is the Chief Executive Officer. The Chief Executive Officer reviews financial information including revenue, expenses and net loss presented on a consolidated basis, accompanied by certain supplemental information about significant expense categories for purposes of allocating resources and evaluating the Company's financial performance. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensors, cameras and AI compute systems and there are no segment managers who are held accountable for operations, operating results and plans for levels or components below the consolidated unit level. The CODM assesses financial performance of the reportable segment and decides how to allocate resources based on the net loss that also is reported as the net loss attributable to the Company on the unaudited condensed consolidated statements of operations and comprehensive loss. The net loss is also used by our CODM to monitor actual results versus budget and prior periods amounts of our reportable segment and decide how to expand business or to return value to stockholders. The measure of the segment assets is reported on the unaudited condensed consolidated balance sheet as total assets.

The following table reflects the significant expenses of our reportable segment (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
Total revenue	\$ 54,626	\$ 35,049	\$ 103,204	\$ 67,681
Less ⁽¹⁾ :				
Product manufacturing costs	25,973	15,059	47,916	31,212
Stock based compensation and amortization expense	2,521	2,260	4,210	3,853
Other costs ⁽²⁾	(553)	1,888	3,555	3,291
Research and development	19,341	17,147	35,423	32,132
Sales and marketing	9,186	6,978	17,026	13,401
General and administrative	18,203	18,539	34,331	34,444
Total other income, net	(2,056)	(2,594)	(4,355)	(4,602)
Provision for (benefit from) income tax expense	125	(3,616)	677	(3,421)
Net loss	\$ (18,114)	\$ (20,612)	\$ (35,579)	\$ (42,629)

⁽¹⁾ The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.

⁽²⁾ Other costs primarily includes inventory excess and obsolescence, scrap, warranty, freight and other cost of revenue items. Amounts for the three and six months ended June 30, 2026, include \$5.4 million of import duty refunds. (See Note 2.)

Note 14. Subsequent Event

On July 2, 2026, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Northland Securities, Inc. as underwriter (the "Underwriter"), pursuant to which the Company agreed to issue and sell an aggregate of 3,621,876 shares of its common stock to the Underwriter (the "Offering"). Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriter a 30-day option, solely for the purpose of covering over-allotments, if any, to purchase up to an additional 543,281 shares of common stock. On August 5, 2026, the option expired unexercised. The price to the public in the Offering was \$55.22 per share.

On July 6, 2026, the Company completed the sale and issuance of an aggregate of 3,621,876 shares of common stock. The Company received net proceeds of approximately \$191.9 million, after deducting the Underwriter's discounts and commissions.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our results of operations and financial condition of Ouster, Inc. ("we," "us," "our," the "Company," "Ouster") should be read together with the information set forth in our unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report, as well as our audited consolidated financial statements and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in Ouster's Annual Report on Form 10-K (the "2025 Annual Report") filed with the SEC on March 2, 2026. This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties, including with respect to the potential future impact of tariffs and other trade measures on the Company's business and results of operations. Ouster's actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled "Risk Factors" in Ouster's 2025 Annual Report and as may be further updated from time to time in the Company's other filings with the SEC. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Overview

Ouster was founded in 2015 with the invention of its high-performance digital lidar and is headquartered in San Francisco, California. We are a leader in sensing and perception for Physical AI across industrial, robotics, automotive, and smart infrastructure. With a unified platform of high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and AI models, Ouster delivers solutions that improve quality of life by enabling machines to sense, think, act, and learn in the physical world. To grow our business, we have introduced new product lines and made several acquisitions to accelerate growth. We continue to invest in growing our hardware product portfolio, increasing the capabilities of our software solutions, and opportunistically expanding our sales and marketing efforts.

We are a leading global provider of lidar sensors and solutions. We design and manufacture high-resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets, which allows each to understand and visualize the surrounding world and enable safe operation and autonomy. We believe our sensors are one of the highest-performing, lowest-cost lidar solutions available today.

Our wholly-owned subsidiary, Stereolabs, which we acquired on February 4, 2026, is a pioneer in AI vision and perception solutions that has developed a leading portfolio of industrial-grade ZED-cameras, AI compute powered by NVIDIA's platform, and in-house AI vision software to power solutions across robotics, industrials, and smart infrastructure. Its high-performance ZED cameras provide best-in-class 2D and 3D color data with ultra-low latency, and its embedded AI compute hardware facilitates native, real-time sensor fusion at the edge. We believe Stereolabs's perception software, built on proprietary AI models, is the foundation for thousands of developers' autonomy workflows. The Stereolabs acquisition positions Ouster as the foundational end-to-end sensing and perception platform for Physical AI.

We have invested heavily in patents since our inception, pursuing comprehensive coverage of invention families and use cases, with broad international coverage.

We believe that our extensive patent coverage creates material barriers to entry.

Products and Solutions

Ouster's hardware product offerings include a broad portfolio of digital lidar sensors, monocular and stereo cameras, and AI compute. On May 4, 2026, we announced the launch of the Rev8 OS family of digital lidar sensors. Powered by our next-generation L4 and L4 Max Ouster Silicon, the Rev8 family features upgraded OS0, OS1, and OSDome sensors and adds the flagship 256-channel OS1 Max. Rev8 introduces the world's first native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. Within our OS sensor models, we offer numerous customization options, all enabled by embedded software.

In addition, our portfolio has expanded to include Stereolabs's growing product line, which now includes the ZED X, ZED X Mini, and ZED X Nano stereo cameras, the ZED X One monocular camera, and the ZED Box edge compute. We are currently developing our solid-state digital flash ("DF") sensors, which is a suite of short, mid, and long-range solid-state digital lidar sensors that provide uniform precision imaging without motion blur across an entire field of view.

Ouster provides Physical AI solutions tailored for smart infrastructure applications. Our software solutions, built on proprietary AI models, enable real-time people and object detection, classification, and tracking for actionable, intuitive, and customizable insights while preserving personally identifiable information. Ouster Gemini is our digital lidar powered perception platform designed for security and crowd analytics, logistics, and intelligent transportation systems. Ouster BlueCity is our turnkey real-time traffic management solution for analytics and signal actuation to improve traffic flow, road safety, and urban planning.

Factors Affecting Our Performance

Commercialization of Our Product Offerings. As our customers continue research and development projects that rely on lidar, or a combination of lidar, camera, and AI compute for Physical AI, it is difficult to estimate the timing of ultimate end market and customer adoption. As a result, we expect that our results of operations, including revenue and gross margins, will improve over time but may fluctuate on a quarterly and annual basis for the foreseeable future. As more customers reach a commercialization phase with solutions that rely on our technology, the fluctuations in our operating results may become less pronounced. Our strategic business objectives also include growing the software-attached business, transforming the product portfolio, and executing towards profitability.

Number of Customers in Production. For certain strategic customers and markets, our products must be integrated into a broader platform, which then must be tested and validated to achieve system-level performance and reliability thresholds that enable commercial production and sales. The time necessary to reach commercial production varies from six months to several years, based on the market and application. For example, the production cycle in the automotive market tends to be substantially longer than in our other target markets. It is critical to our future success in each of our target end markets that our customers reach commercial production and select our products in their commercial production applications, and that we avoid unexpected cancellations of major purchases of our products. Because the timelines to reach production vary significantly and the revenue generated by each customer in connection with commercial production is unpredictable, it is difficult for us to reliably predict our financial performance.

Customers' Sales Volumes. Our customer base is diversified, and we aim to continue to penetrate diverse end markets to increase our sales volumes. Ultimately, widespread adoption of our customers' products that incorporate our lidar solutions will depend on many factors, including the size of our customers' end markets, market penetration of our customers' products that incorporate our digital lidar solutions, our customers' ability to sell their products, and the financial stability and reputation of our customers.

Average Selling Prices ("ASPs"), Product Costs and Margins. Our product costs and gross margins depend largely on the volumes of sensors shipped, the mix of existing and new products sold and the number and variety of solutions we provide to our customers. We expect that our selling prices will vary by target end market and application due to market-specific supply and demand dynamics. We expect to continue to experience some downward pressure on prices from signing anticipated large multi-year agreements in the near term with multi-year negotiated pricing. We expect that these customer-specific selling price fluctuations combined with our volume-driven product costs may drive fluctuations in revenue and gross margins on a quarterly basis. In addition, we expect that the current uncertainty surrounding U.S. trade relationships may impact our future product costs and margins, particularly to the extent there are significant tariffs or trade restrictions imposed on goods imported from Thailand, Canada, Taiwan or China that are used in our products. Although we are taking steps to mitigate the impacts of potential tariffs, we do not expect to be able to offset or avoid such costs in full. In addition, our contractual arrangements generally provide that our customers will pay the costs of tariffs. These costs could impact customer demand and adoption as described above under "Customers' Sales Volumes."

Competition. Lidar is an emerging technology, and there are many competitors for this growing market which has created downward pressure on our ASPs. Absent the introduction of new technology, we expect this pressure to continue to push our ASPs lower in the coming years. However, we believe that because of the simplicity of our digital lidar technology, the increasing capabilities of our software solutions, the value of a complete end-to-end sensing and perception platform, and efficiencies created by our established manufacturing partnerships and suppliers, including Benchmark and Fabrinet. We are well-positioned to scale a set of differentiated offerings that allows us to sustain and potentially increase our gross margins and mitigate pricing pressure over time.

Continued Investment and Innovation. We believe that we are a leading 3D sensing provider. Our financial performance is significantly dependent on our ability to maintain this leading position, which is further dependent on the investments we make in research and development. We believe it is essential that we continue to identify and respond to rapidly evolving customer requirements, including successfully progressing our sensing and perception platform roadmap and developing technologies that will enhance the operating performance of our products. We announced our Rev8 family of products. Our "Chronos" chip has been fabricated by our foundry partner and is now undergoing in-house testing. If we fail to continue our innovation, our market position and revenue may be adversely affected, and our investments in that area will not be recovered.

Supply Chain Continuity. Some of the key components in the products we have designed or are currently designing come from limited or single source suppliers. If these third parties experience financial, operational, manufacturing capacity or other difficulties, or experience shortages in required components, or if they are otherwise unable or unwilling to continue to manufacture these components in required volumes or at all, our supply may be disrupted or be on less favorable terms. For example, we may be required to seek alternate manufacturers or suppliers for our products. It would be time-consuming, and could be costly and impracticable, to begin to use and qualify new manufacturers, components or designs, and such changes could cause significant interruptions in supply and could have an adverse effect on our ability to meet our scheduled product deliveries and may subsequently lead to the loss of sales.

We continue to monitor the impact of tariff and trade policy actions taken by the United States and foreign governments on our supply chain. During the three and six months ended June 30, 2026, the Company received cash refunds in the amount of \$0.6 million IEEPA import duties. Additionally, included in prepaid expenses and other current assets as of June 30, 2026, is a \$4.8 million IEEPA import duty refund receivable which was received in July 2026. We continue to review the potential impact of the global duty, tariff and value-added tax landscape on the Company and any available mitigation strategies.

Market Trends and Uncertainties. We anticipate increasing demand for our sensing and perception platform. We estimate a multi-billion dollar total addressable market (“TAM”) for our solutions in the future. We define our TAM as applications in the automotive, industrial, robotics, and smart infrastructure end markets where we actively engage and maintain customer relationships. Each of our target markets is potentially a significant global opportunity, and these markets have historically been underserved by limited or inferior technology or not served at all. We believe we are well-positioned in our market as a leading provider of high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and AI models.

We may not be able to take advantage of demand if we are unable to anticipate regulatory changes and adapt quickly enough to meet such new regulatory standards or requirements applicable to us or to our customers’ products in which our lidar sensors are used. Market acceptance of lidar technology and active safety technology depend upon many factors, including cost, performance, quality and reliability, safety performance, regulatory requirements and international taxes or tariff and trade policy actions of governments related to such technologies. These factors may impact the ultimate market acceptance of our lidar technology.

International Expansion. We view international expansion as an important element of our strategy to increase revenue and achieve profitability. We continue to position ourselves in geographic markets that we expect to serve as important sources of future growth. We have an existing presence in three regions: Americas; Asia and Pacific; and Europe, Middle East and Africa. We intend to expand our presence in these regions over time including through distribution partnerships. Expanded global reach will require continued investment and may expose us to additional foreign currency risk, international taxes, tariff and trade policy actions of foreign governments, legal obligations, geopolitical conflict, including war in the Middle East, export/import regulations and additional operational costs. These risks and challenges may impact our ability to meet our projected sales volumes, revenues, and gross margins. In addition, the current uncertainty surrounding U.S. trade relationships may impact our future international sales, particularly to the extent there are significant tariffs or trade restrictions imposed on goods imported from the United States.

Employee Retention Credit. The employee retention credit (“ERC”), as originally enacted through the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020, is a refundable credit against certain employment taxes. The Company qualified for the ERC for the period between March 17, 2020 and September 30, 2021 and the Company received an ERC credit in the amount of \$5.4 million in the three months ended June 30, 2025.

Components of Results of Operations

Revenue

The majority of our revenue comes from the sale of our lidar sensors, cameras, and AI compute systems both directly to end users and through distributors both domestically and internationally. We recognize revenue from product sales when the performance obligation of transferring control of the product to the customer has been met, generally when the product is shipped. We also recognize revenue by performing services or obligations related to product development, validation, IP license agreements, maintenance under our extended warranty contracts, and shipping. We do not expect these services to be material components of revenue, cost of revenue or gross margin in the near future. Performance obligations related to services are generally recognized over time, based on cost-to-cost input basis or straight-line over time. Amounts billed to customers related to shipping and handling are classified as revenue, and we have elected to recognize the cost of shipping activities that occur after control has transferred to the customer as a fulfillment cost rather than a separate performance obligation. All related costs are accrued and recognized within cost of revenue when the related revenue is recognized.

Most of our customers are innovators and early technology adopters incorporating our products into their solutions. Currently, our product revenue consists of both customers ordering small volumes of our products that are in an evaluation phase and customers that order larger volumes of our products and have more predictable long-term production schedules. However, we believe we are still at the very beginning of the adoption curve, and some customers are still learning their growth and demand rates which can impact the timing of purchase orders quarter to quarter. As we grow our business, we expect to continue to improve our own understanding of our customers' needs and timelines, and expect the timing of orders will have a less notable impact on our quarterly results.

Cost of Revenue

Cost of revenue consists of the manufacturing cost components, personnel-related expenses, including salaries, benefits, and stock-based compensation directly associated with our manufacturing organization, and amounts paid to our third-party contract manufacturer and vendors. Our cost of revenue also includes depreciation of manufacturing equipment, amortization of intangible assets, an allocated portion of overhead, facility and information technology ("IT") costs, warranty expenses, excess and obsolete inventory, tariffs, shipping costs and merchant fees.

Gross Profit and Gross Margin

Our gross profit equals total revenues less our total cost of revenues, and our gross margin is our gross profit expressed as a percentage of total revenue. Our gross margin is subject to quarterly fluctuations in product mix, price and volume.

Operating Expenses

Research and Development Expenses

Research and development ("R&D") activities are primarily conducted at our San Francisco headquarters and our additional R&D facilities in France, Scotland and Canada and consist of the following activities:

- Design, prototyping, and testing of proprietary electrical, optical, and mechanical subsystems for our products;
- Robust testing for safety certifications;
- Development of new products and enhancements to existing products in response to customer requirements including firmware and software development of lidar and camera integration products;
- Custom SoC design for Ouster's digital lidar products; and
- Development of custom manufacturing equipment.

R&D expenses consist of personnel-related expenses, including salaries, benefits, and stock-based compensation, for all personnel directly involved in R&D activities, third-party engineering and contractor costs, prototype expenses, amortization of intangible assets, and an allocated portion of overhead, facility and information technology ("IT") costs that support R&D activities.

R&D costs are expensed as they are incurred. Our investment in R&D will continue to grow as we invest in new lidar technology and related software. Our absolute amount of R&D expenses is expected to grow over time; however, we expect R&D as a percentage of revenue to decrease as our business grows.

Sales and Marketing Expenses

Our business development, customer support and marketing teams are located in offices worldwide. Selling and marketing expenses consist of personnel-related expenses, including salaries, commissions, benefits, and stock-based compensation, for all personnel directly involved in business development, customer support, and marketing activities, and marketing expenses including trade shows, advertising, and demonstration equipment. Sales and marketing expenses also include amortization expense of intangible assets related to customer relationships and a trade name associated with the acquisitions and an allocated portion of facility and IT costs that support sales and marketing activities. We expect sales and marketing expenses as a percentage of revenue to decrease over time as our business grows.

General and Administrative Expenses

General and administrative expenses consist of personnel-related expenses, including salaries, benefits, and stock-based compensation, of our executives and members of the board of directors, finance, human resources, an allocated portion of facility and IT costs that support general and administrative activities, as well as amortization of intangible assets, legal fees, patent prosecution, accounting, finance and professional services, as well as insurance and bank fees. We have experienced and may in the near-term experience additional increases in general and administrative expenses related to legal, accounting, finance and professional services costs associated with acquisition-related transaction and integration costs, litigation activities, hiring more personnel and consultants to support our international expansion and compliance with the applicable provisions of the Sarbanes-Oxley Act and other SEC rules and regulations as a result of being a public company. Our absolute amount of general and administrative expenses will grow over time; however, we expect general and administrative expenses as a percentage of revenue to decrease as our business grows.

Interest Income and Other Income (Expense), Net

Interest income consists primarily of income earned on our cash and cash equivalents and short-term investments. These amounts will vary based on our respective balances and market rates. Other income (expense), net consists primarily of change in fair value with foreign currency forward contracts, realized and unrealized gains and losses on foreign currency transactions and balances, realized gains and losses related to sales of our available-for-sale investments.

Income Taxes

Our income tax provision consists of federal, state and foreign current and deferred income taxes. Our income tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items arising in the quarter. Our effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on deferred tax assets as it is more likely than not that some, or all, of our deferred tax assets will not be realized. We continue to maintain a full valuation allowance against our U.S. Federal, state and certain foreign deferred tax assets, excluding specific balances related to the Stereolabs acquisition. The income tax provision for the three and six months ended June 30, 2026 was \$0.1 million and \$0.7 million, respectively. The income tax provision for the six months ended June 30, 2026 includes \$0.9 million of discrete items primarily related to withholding taxes on sales to customers. Discrete items for the three months ended June 30, 2026, were not significant. The income tax benefit for the three and six months ended June 30, 2025 was \$3.6 million and \$3.4 million, respectively and is primarily related to the resolution of an IRS examination of the Company's 2017 and 2018 tax years offset by income taxes for its foreign operations.

Results of Operations:

The results of operations presented below should be reviewed in conjunction with the unaudited condensed consolidated financial statements and notes included elsewhere in this Quarterly Report. The following table sets forth our unaudited condensed consolidated results of operations data for the periods presented:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
	(in thousands)			
Revenue:				
Product revenue	\$ 52,763	\$ 35,015	\$ 100,994	\$ 66,120
Royalties	1,863	34	2,210	1,561
Total revenue	54,626	35,049	103,204	67,681
Cost of revenue ⁽¹⁾	27,941	19,207	55,681	38,356
Gross profit	26,685	15,842	47,523	29,325
Operating expenses ⁽¹⁾ :				
Research and development	19,341	17,147	35,423	32,132
Sales and marketing	9,186	6,978	17,026	13,401
General and administrative	18,203	18,539	34,331	34,444
Total operating expenses	46,730	42,664	86,780	79,977
Loss from operations	(20,045)	(26,822)	(39,257)	(50,652)
Other income (expense):				
Interest income	2,116	2,620	4,444	4,325
Other income (expense), net	(60)	(26)	(89)	277
Total other income, net	2,056	2,594	4,355	4,602
Loss before income taxes	(17,989)	(24,228)	(34,902)	(46,050)
Provision for (benefit from) income tax expense	125	(3,616)	677	(3,421)
Net loss	\$ (18,114)	\$ (20,612)	\$ (35,579)	\$ (42,629)

The following table sets forth the components of our unaudited condensed consolidated statements of operations and comprehensive loss data as a percentage of total revenue for the periods presented:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
	(% of total revenue)			
Revenue:				
Product revenue	97 %	100 %	98 %	98 %
Royalties	3	—	2	2
Total revenue	100	100	100	100
Cost of revenue ⁽¹⁾	51	55	54	57
Gross profit	49	45	46	43
Operating expenses ⁽¹⁾				
Research and development	35	49	34	47
Sales and marketing	17	20	16	20
General and administrative	33	53	33	51
Total operating expenses	86	122	84	118
Loss from operations	(37)	(77)	(38)	(75)
Other income (expense):				
Interest income	4	7	4	6
Other income (expense), net	—	—	—	—
Total other income, net	4	7	4	6
Loss before income taxes	(33)	(70)	(34)	(69)
Provision for (benefit from) income tax expense	—	(10)	1	(5)
Net loss	(33)%	(60)%	(35)%	(64)%

⁽¹⁾ Includes stock-based compensation expense as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025
	(in thousands)			
Cost of revenue	\$ 1,395	\$ 1,799	\$ 2,221	\$ 2,935
Research and development	4,332	6,303	6,948	10,608
Sales and marketing	1,177	1,733	1,943	2,839
General and administrative	4,481	3,391	7,767	5,342
Total stock-based compensation	\$ 11,385	\$ 13,226	\$ 18,879	\$ 21,724

Comparison of the three months ended June 30, 2026 and 2025

Revenue

	Three Months Ended June 30,		Change	Change
	2026	2025	\$	%
(dollars in thousands)				
Revenue by geographic location:				
Americas	\$ 35,427	\$ 24,548	\$ 10,879	44 %
Asia and Pacific	12,566	6,096	6,470	106
Europe, Middle East and Africa	6,633	4,405	2,228	51
Total	<u>\$ 54,626</u>	<u>\$ 35,049</u>	<u>\$ 19,577</u>	<u>56 %</u>

Revenue

Revenue increased by \$19.6 million or 56%, to \$54.6 million for the three months ended June 30, 2026 from \$35.0 million for the comparable period in the prior year. The increase in revenue was primarily driven by increased sensor volumes as customers increased their purchase levels compared to the prior year period, offset in part by decreased ASPs. The increase was also attributable, in part, to the inclusion of revenue from products acquired through the Stereolabs acquisition, for which there was no comparable revenue contribution in the prior-year period.

We recorded \$1.9 million in patent royalty revenue for the three months ended June 30, 2026. Patent royalty revenue for the three months ended June 30, 2025, was not significant.

Cost of Revenue

	Three Months Ended June 30,		Change	Change
	2026	2025	\$	%
(dollars in thousands)				
Cost of revenue	\$ 27,941	\$ 19,207	\$ 8,734	45 %

Cost of revenue increased by \$8.7 million, or 45%, to \$27.9 million for the three months ended June 30, 2026 from \$19.2 million for the comparable period in the prior year. The increase in cost of revenue was primarily attributable to higher shipments, the inclusion of manufacturing costs from our recently-acquired subsidiary, Stereolabs, higher amortization costs from acquired intangible assets and higher excess and obsolete inventory charges, offset in part by IEEPA import duty refunds. Cost of revenue for the three months ended June 30, 2026 included a \$5.4 million cost reduction associated with the IEEPA import duty refunds. Cost of revenue for the three months ended June 30, 2025 included a \$1.7 million cost reduction associated with the ERC that was received during the period.

Gross margin rose to 49% for the three months ended June 30, 2026 from 45% in the prior year period primarily due to increased sensor volumes and IEEPA import duty refunds.

Operating Expenses

	Three Months Ended June 30,		Change	Change
	2026	2025	\$	%
(dollars in thousands)				
Operating expenses:				
Research and development	\$ 19,341	\$ 17,147	\$ 2,194	13 %
Sales and marketing	9,186	6,978	2,208	32
General and administrative	18,203	18,539	(336)	(2)
Total operating expenses	<u>\$ 46,730</u>	<u>\$ 42,664</u>	<u>\$ 4,066</u>	<u>10 %</u>

Research and Development

Research and development expenses increased by \$2.2 million, or 13%, to \$19.3 million for the three months ended June 30, 2026 from \$17.1 million for the comparable period in the prior year. The increase was primarily attributable to the inclusion of Stereolabs and the increase in compensation expenses for employees engaged in research and product development function, offset in part by lower prototype materials and lower stock compensation expense. Additionally, in the three months ended June 30, 2025, the Company recognized \$2.2 million in benefits resulting from an ERC as a reduction to research and development expenses.

Sales and Marketing

Sales and marketing expenses increased by \$2.2 million, or 32%, to \$9.2 million for the three months ended June 30, 2026 from \$7.0 million for the comparable period in the prior year. The increase was primarily attributable to the inclusion of Stereolabs and the increase in the amortization of acquisition-related intangible assets, offset in part by lower stock compensation expense. Additionally, in the three months ended June 30, 2025, the Company recognized \$0.7 million benefits that were received resulting from an ERC as a reduction to the sales and marketing expenses.

General and Administrative

General and administrative expenses decreased by \$0.3 million, or 2%, to \$18.2 million for the three months ended June 30, 2026 from \$18.5 million for the comparable period in the prior year. The decrease was primarily attributable to lower litigation and settlement activities, offset in part by transaction and integration costs associated with the Stereolabs acquisition, and increased stock compensation expense. Additionally, in the three months ended June 30, 2025, the Company recognized \$0.8 million ERC benefits, that were received as a reduction to the general and administrative expenses.

Interest Income and Other Income (Expense), Net

	Three Months Ended June 30,		Change	Change
	2026	2025	\$	%
	(dollars in thousands)			
Interest income	\$ 2,116	\$ 2,620	\$ (504)	(19)%
Other income (expense), net	(60)	(26)	(34)	131
Total interest income and other income (expense), net	\$ 2,056	\$ 2,594	\$ (538)	(21)

The year-over-year change in interest income is primarily due to the receipt of interest income on an IRS payment during the three months ended June 30, 2025 that did not reoccur, partially offset by a higher average investment balance during the three months ended June 30, 2026.

During the three months ended June 30, 2026, the Company recognized \$0.2 million in interest income earned on IEEPA import duty refunds.

During the three months ended June 30, 2025, the Company recognized \$0.8 million in interest income earned on a delayed IRS payment related to ERC claims.

Income Taxes

We were subject to income taxes in the United States and miscellaneous foreign jurisdictions for the three months ended June 30, 2026 and 2025. The Company's income tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items arising in the quarter.

The Company's effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on the deferred tax assets as it is more likely than not that some, or all, of the Company's deferred tax assets will not be realized. The Company continues to maintain a full valuation allowance against our U.S. Federal, state and certain foreign deferred tax assets, excluding specific balances related to the Stereolabs acquisition.

The tax provision for the three months ended June 30, 2026 was \$0.1 million. For the three months ended June 30, 2025, the Company recorded an income tax benefit of \$3.6 million primarily related to the resolution of the Company's IRS examination of its 2017 and 2018 tax years offset by income taxes for its foreign operations.

Comparison of the six months ended June 30, 2026 and 2025

Revenue

	Six Months Ended June 30,		Change	
	2026	2025	\$	%
(dollars in thousands)				
Revenue by geographic location:				
Americas	\$ 68,225	\$ 40,076	\$ 28,149	70 %
Asia and Pacific	20,556	18,560	1,996	11
Europe, Middle East and Africa	14,423	9,045	5,378	59
Total	<u>\$ 103,204</u>	<u>\$ 67,681</u>	<u>\$ 35,523</u>	<u>52 %</u>

Revenue

Revenue increased by \$35.5 million, or 52%, to \$103.2 million for the six months ended June 30, 2026, from \$67.7 million for the comparable period in the prior year. The increase in revenue was primarily driven by increased sensor volumes as customers increased their purchase levels compared to the prior year period, offset in part by decreased ASPs. The increase was also attributable, in part, to the inclusion of revenue from products acquired through the Stereolabs acquisition, for which there was no comparable revenue contribution in the prior-year period.

We recorded \$2.2 million and \$1.6 million, respectively in patent royalty revenue for the six months ended June 30, 2026 and six months ended June 30, 2025.

Cost of Revenue

	Six Months Ended June 30,		Change	
	2026	2025	\$	%
(dollars in thousands)				
Cost of revenue	\$ 55,681	\$ 38,356	\$ 17,325	45 %

Cost of revenue increased by \$17.3 million, or 45%, to \$55.7 million for the six months ended June 30, 2026 from \$38.4 million for the comparable period in the prior year. The increase in cost of revenue was primarily attributable to higher product shipments, the inclusion of manufacturing costs from our recently-acquired subsidiary, Stereolabs, higher amortization costs from acquired intangible assets and higher excess and obsolete inventory charges, partially offset by IEEPA import duty refunds. Cost of revenue for the six months ended June 30, 2026 included a \$5.4 million cost reduction associated with IEEPA import duty refunds. Cost of revenue for the six months ended June 30, 2025 included a \$1.7 million cost reduction associated with the ERC that was received during the period.

Operating Expenses

	Six Months Ended June 30,		Change	
	2026	2025	\$	%
(dollars in thousands)				
Operating expenses:				
Research and development	\$ 35,423	\$ 32,132	\$ 3,291	10 %
Sales and marketing	17,026	13,401	3,625	27
General and administrative	34,331	34,444	(113)	—
Total operating expenses	<u>\$ 86,780</u>	<u>\$ 79,977</u>	<u>\$ 6,803</u>	<u>9 %</u>

Research and Development

Research and development expenses increased by \$3.3 million, or 10%, to \$35.4 million for the six months ended June 30, 2026 from \$32.1 million for the comparable period in the prior year. The increase is primarily attributable to the inclusion of Stereolabs, the Company's continuing investment in the research and development of new product offerings, and higher salaries and wages, offset in part by lower prototype materials expense and lower stock compensation expense. Additionally, in

the six months ended June 30, 2025, the Company recognized \$2.2 million in benefits resulting from an ERC as a reduction to research and development expenses.

Sales and Marketing

Sales and marketing expenses increased by \$3.6 million, or 27%, to \$17.0 million for the six months ended June 30, 2026 from \$13.4 million for the comparable period in the prior year. The increase was primarily attributable to the inclusion of Stereolabs and the increase in the amortization of acquisition-related intangible assets, offset in part by lower stock compensation and commission expenses. Additionally, in the six months ended June 30, 2025, the Company recognized \$0.7 million benefits that were received resulting from an ERC as a reduction to the sales and marketing expenses.

General and Administrative

General and administrative expenses decreased by \$0.1 million, or essentially flat, to \$34.3 million for the six months ended June 30, 2026 from \$34.4 for the comparable period in the prior year. The decrease was primarily attributable lower litigation and settlement activities, offset in part by transaction and integration costs associated with the Stereolabs acquisition and higher stock compensation expense. Additionally, in the six months ended June 30, 2025, the Company recognize \$0.8 million ERC benefits, that were received as a reduction to the general and administrative expenses.

Interest Income and Other Income (Expense), Net

	Six Months Ended June 30,		Change	Change
	2026	2025	\$	%
	(dollars in thousands)			
Interest income	\$ 4,444	\$ 4,325	\$ 119	3 %
Other income (expense), net	(89)	277	(366)	(132)
Total interest income and other income (expense), net	4,355	4,602	(247)	(5)

The year-over-year interest income earned increased due to higher cash and short-term invested balances offset by lower average rate of interest earned on held balances. During the six months ended June 30, 2026, the Company recognized \$0.6 million interest income earned on an IRS income tax refund received during the period and \$0.2 million interest income earned on IEEPA import duty refunds. During the six months ended June 30, 2025, the Company recognized \$0.8 million in interest income earned on a delayed IRS payment related to ERC claims.

Other income (expense), net was not material for the six months ended June 30, 2026 and 2025.

Income Taxes

The Company's income tax provision for interim periods is determined using an estimate of the Company's annual effective tax rate, adjusted for discrete items arising in the quarter. The Company's effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on the deferred tax assets as it is more likely than not that some, or all, of the Company's deferred tax assets will not be realized. The Company continues to maintain a full valuation allowance against our U.S. Federal, state and certain foreign deferred tax assets, excluding specific balances related to the Stereolabs acquisition.

The tax provision for the six months ended June 30, 2026, was \$0.7 million, which includes \$0.9 million of discrete items primarily related to withholding taxes on sales to customers. For the six months ended June 30, 2025, the Company recorded an income tax benefit of \$3.4 million primarily related to the resolution of the Company's IRS examination of its 2017 and 2018 tax years offset by income taxes for its foreign operations.

Liquidity and Capital Resources

Our principal sources of liquidity are our cash and cash equivalents and short-term investments, cash generated from sales of our products, and sales of common stock under our at-the market equity offering program.

Our primary requirements for liquidity and capital are to finance working capital, inventory management, capital expenditures and general corporate purposes. We expect these needs to continue as we develop and grow our business.

As of June 30, 2026, we had an accumulated deficit of \$1.0 billion and cash, cash equivalents, restricted cash and short-term investments of \$262.5 million. Management believes that our existing sources of liquidity will be sufficient to fund our operations for at least twelve months from the date of this Quarterly Report.

We manage our cash and cash equivalents with financial institutions that we believe have high credit quality and, at times, such amounts exceed federally insured limits. The failure of any bank with which we maintain a commercial relationship could cause us to lose our deposits in excess of the federally insured or protected amounts. We have experienced recurring losses from operations, and negative cash flows from operations, and we expect to continue operating at a loss and to have negative cash flows from operations for the foreseeable future. Because we are in the growth stage of our business and operate in an emerging field of technology, we expect to continue to invest in research and development and opportunistically expand our sales and marketing teams worldwide. We may require additional capital to respond to technological advancements, competitive dynamics or technologies, customer demands, business opportunities, challenges, acquisitions, or unforeseen circumstances and in either the short-term or long-term may determine to engage in equity or debt financings, or may choose to raise additional capital opportunistically if we believe market conditions are favorable. If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited. In particular, current macroeconomic conditions, including elevated inflation rates and high interest rates, have resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital. If we are unable to raise additional funds when or on the terms desired, our business, financial condition and results of operations could be adversely affected.

ATM Agreement

On May 12, 2025, the Company entered into an At-Market-Issuance Sales Agreement (the “Former ATM Agreement”) with Oppenheimer & Co. Inc., pursuant to which the Company could offer and sell shares of the Company’s common stock, having an aggregate offering price of up to \$100.0 million.

The Company terminated the Former ATM Agreement in May 2026.

From the date of the Former ATM Agreement to its termination, the Company sold 4,671,406 shares at a weighted-average sales price of \$20.88 per share, resulting in cumulative gross proceeds to the Company totaling approximately \$97.5 million before deducting offering costs, sales commissions and fees. Cumulative net proceeds to the Company totaled approximately \$95.6 million after deducting offering costs, sales commissions and fees.

On May 8, 2026, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with Oppenheimer & Co. Inc., Northland Securities, Inc., Rosenblatt Securities Inc., and Roth Capital Partners, LLC (each, an “Agent” and, collectively the “Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Agents, acting as agent or principal, shares of the Company’s common stock, having an aggregate offering price of up to \$100.0 million.

During the three months ended June 30, 2026, 3,649,000 shares of common stock were sold under the ATM Agreement at a weighted-average sales price of \$27.40 per share, resulting in cumulative gross proceeds to the Company totaling approximately \$100.0 million before deducting offering costs, sales commissions and fees. Cumulative net proceeds to the Company totaled approximately \$98.0 million after deducting offering costs, sales commissions and fees. We plan to use the net proceeds from this offering for working capital and general corporate purposes. As of June 30, 2026, the ATM offering is complete and there are no remaining funds availability under the ATM Agreement.

July 2026 Offering

On July 2, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Northland Securities, Inc. as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell an aggregate of 3,621,876 shares of common stock to the Underwriter (the “Offering”). Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriter a 30-day option, solely for the purpose of covering over-allotments, if any, to purchase up to an additional 543,281 shares of common stock. The price to the public in the Offering was \$55.22 per share.

On July 6, 2026, the Company completed the sale and issuance of an aggregate of 3,621,876 shares of common stock. The Company received net proceeds of approximately \$191.9 million, after deducting the Underwriter’s discounts and commissions.

Material Cash Requirements

We are a party to many contractual obligations involving commitments to make payments to third parties. These obligations impact our short-term and long-term liquidity and capital resource needs. Certain contractual obligations are reflected on the unaudited condensed consolidated balance sheet as of June 30, 2026, while others are considered future commitments. Our contractual obligations primarily consist of non-cancelable purchase commitments with various parties to purchase goods or services, primarily inventory, entered into in the normal course of business and operating leases. For information regarding our other contractual obligations, refer to Note 7. Commitments and Contingencies to our unaudited condensed consolidated financial statements included in this Quarterly Report as well as Note 7. Leases and Note 8. Commitments and Contingencies Part II, Item 8 of our 2025 Annual Report.

Cash Flow Summary

The following table summarizes our cash flows from continuing operations for the periods presented:

	Six Months Ended June 30,	
	2026	2025
	(in thousands)	
Net cash (used in) provided by:		
Operating activities	\$ (20,039)	\$ (6,188)
Investing activities	\$ (60,014)	\$ (23,877)
Financing activities	\$ 103,268	\$ 60,173

Operating Activities

During the six months ended June 30, 2026, operating activities used \$20.0 million in cash. The primary factors affecting our operating cash flows during this period were our net loss of \$35.6 million, offset by our non-cash charges of \$27.0 million, primarily consisting of depreciation and amortization of \$5.9 million, stock-based compensation of \$18.9 million, amortization of right-of-use asset of \$1.7 million, partially offset by accretion on short-term investments of \$1.1 million. The changes in our operating assets and liabilities of \$11.5 million were primarily due to a decrease in accounts receivable of \$10.6 million, increase in inventory of \$5.7 million, an increase in prepaid expenses and other assets of \$9.9 million, an increase in accounts payable of \$0.8 million, a decrease in contract liabilities of \$5.6 million and decrease in operating lease liability of \$1.9 million.

During the six months ended June 30, 2025, operating activities used \$6.2 million in cash. The primary factors affecting our operating cash flows during this period were our net loss of \$42.6 million, offset by our non-cash charges of \$28.3 million, primarily consisting of depreciation and amortization of \$3.7 million, stock-based compensation of \$21.7 million and amortization of right-of-use asset of \$2.5 million, partially offset by accretion or amortization on short-term investments of \$1.5 million. The changes in our operating assets and liabilities of \$8.2 million were primarily due to a decrease in accounts receivable of \$6.5 million, decrease in inventory of \$2.0 million, an increase in prepaid expenses and other assets of \$3.6 million, an increase in accounts payable of \$6.4 million, an increase in accrued and other liabilities of \$4.0 million, a decrease in contract liabilities of \$3.8 million and decrease in operating lease liability of \$3.3 million.

Investing Activities

During the six months ended June 30, 2026, cash used by investing activities was \$60.0 million, consisting primarily of \$122.3 million purchases of short-term investments and \$27.5 million used for the acquisition of Stereolabs, net of cash acquired, partially offset by \$95.0 million in proceeds from the sale and maturities of short-term investments.

During the six months ended June 30, 2025, cash used by investing activities was \$23.9 million, consisting primarily of purchases of short-term investments of \$79.7 million partially offset by \$57.3 million proceeds from sales and maturities of short-term investments.

Financing Activities

During six months ended June 30, 2026, cash provided by financing activities of \$103.3 million was primarily related to the issuance of \$98.0 million in common stock under the ATM Agreement.

During the six months ended June 30, 2025, cash provided by financing activities of \$60.2 million was primarily from the issuance of common stock under the Former ATM Agreement.

Critical Accounting Policies and Estimates

Our critical accounting estimates are described in Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2025 Annual Report. There have been no significant changes to our critical accounting policies and estimates since the filing of our 2025 Annual Report.

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions. Certain of these policies require the application of subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. These estimates and assumptions are based on historical experience, changes in the business environment and other factors that we believe to be reasonable under the circumstances. Different estimates that could have been applied in the current period or changes in the accounting estimates that are reasonably likely can result in a material impact on our financial condition and operating results in the current and future periods.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates, foreign currency exchange rates and to a lesser extent, inflation risk. The following analysis provides quantitative and qualitative information regarding these risks.

Inflation Risk

General inflation in the U.S., Europe and other geographies has risen significantly in recent years. To date, we do not believe that inflation has had a material effect on our business, financial condition, or results of operations, other than its impact on the general economy. However, we are monitoring the current inflationary environment, particularly as it may be impacted by proposed and/or newly implemented tariffs. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases, and our inability or failure to do so could harm our business, financial condition and results of operations.

Interest Rate Risk

As of June 30, 2026, we had cash and cash equivalents, restricted cash and short-term investments of \$262.5 million, of which \$68.8 million consisted of institutional money market funds, \$97.9 million consisted of commercial paper, and \$71.4 million consisted of corporate debt securities, all of which carries a degree of interest rate risk. The primary goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes.

These investments are subject to interest rate risk, as sharp increases in market interest rates could have an adverse impact on their fair value. Although the fair values of these instruments can fluctuate, we believe that the short-term, highly liquid nature of these investments, and our ability to hold these instruments to maturity, reduces our risk for potential material losses. A hypothetical 100 basis point change in interest rates would not have a material impact on our financial condition or results of operations due to the short-term nature of our investment portfolio.

As of June 30, 2026, we had no debt outstanding and therefore are not exposed to interest rate risk with respect to debt.

Foreign Currency Exchange Risk

Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. Substantially all of our revenue is generated in U.S. dollars. Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the U.S. and to a lesser extent in Asia and Europe.

The effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business would not have a material impact on our historical consolidated financial statements.

As our international operations grow, we will continue to reassess our approach to managing our risk relating to fluctuations in currency rates. However, no strategy can completely insulate us from risks associated with such fluctuations and our currency exchange rate risk management activities could expose us to substantial losses if such rates move materially differently from our expectations.

Item 4. Controls and Procedures

Limitations on Effectiveness of Controls and Procedures

Disclosure controls and procedures include controls and other procedures that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, (“Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management of the Company, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2026. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are, from time to time, party to various claims and legal proceedings arising in the ordinary course of our business. See Note 7. Commitments and Contingencies to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report for a discussion of material legal proceedings.

Item 1A. Risk Factors

Investing in our securities involves a high degree of risk. You should carefully consider the risks described under the heading “Risk Factors” in Part I, Item 1A. of our 2025 Annual Report, the other information in this Quarterly Report, including our unaudited condensed consolidated financial statements and the related notes, as well as our other public filings with the SEC, before deciding to invest in our securities. There have been no material changes to the Company’s risk factors previously disclosed in our 2025 Annual Report. The occurrence of any of the events described therein could harm our business, financial condition, results of operations, liquidity or prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.

None.

(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.

None.

(c) Insider trading arrangements and policies.

On May 19, 2026, Kenneth Gianella, the Company’s Chief Financial Officer, adopted a “Rule 10b5-1 trading arrangement” as defined in Item 408(a) of Regulation S-K. The plan provides for the periodic sale of up to 40,000 shares of common stock between August 18, 2026 and May 19, 2027.

On June 3, 2026, Megan Chung, the Company’s General Counsel and Secretary, adopted a “Rule 10b5-1 trading arrangement” as defined in Item 408(a) of Regulation S-K. The plan provides for the periodic sale of up to 16,000 shares of common stock between October 15, 2026 and February 25, 2027.

Other than as described above, during the three months ended June 30, 2026, no director or officer of the Company, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

Exhibit Number	Description	Incorporated by Reference				Filed/ Furnished herewith
		Form	File No.	Exhibit	Filing Date	
3.1	Certificate of Incorporation of Ouster, Inc.	S-4 POS	333-251611	3.1	3/10/2021	
3.2	Certificate of Amendment to Certificate of Incorporation of Ouster, Inc.	8-K	001-39463	3.1	4/20/2023	
3.3	Second Amended and Restated Bylaws of Ouster, Inc. (effective as of April 18, 2024)	8-K	001-39463	3.1	4/22/2024	
3.4	Certificate of Amendment to Certificate of Incorporation of Ouster, Inc.	8-K	001-39463	3.1	6/18/2026	
4.1	Warrant to Purchase Common Stock of Velodyne Lidar, Inc., by and between Velodyne Lidar, Inc. and Amazon.com NV Investment Holdings LLC, dated as of February 4, 2022	8-K	001-38703	4.1	2/7/2022	
10.1	Sales Agreement, dated May 8, 2026, by and between the Company and Oppenheimer & Co. Inc., Northland Securities, Inc., Rosenblatt Securities Inc., and Roth Capital Partners, LLC	8-K	001-39463	1.1	5/8/2026	
31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended					*
31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended					*
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					**
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					**
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.					*
101.SCH	Inline XBRL Taxonomy Extension Schema Document					*
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document					*
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document					*
101.LAB	Inline XBRL Taxonomy Label Linkbase Document					*
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document					*
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)					*

* Filed herewith.

** Furnished herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 6, 2026

Ouster, Inc.

By: /s/ Kenneth P. Gianella

Name: Kenneth P. Gianella

Title: Chief Financial Officer (*principal financial officer and principal accounting officer*)

CERTIFICATION

I, Angus Pacala, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Ouster, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2026

By: /s/ Angus Pacala
Angus Pacala
Co-Founder and Chief Executive Officer
(*principal executive officer*)

CERTIFICATION

I, Kenneth Gianella, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Ouster, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2026

By: /s/ Kenneth P. Gianella
Kenneth P. Gianella
Chief Financial Officer
(*principal financial officer*)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Ouster, Inc. (the “Company”) for the period ended June 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2026

By: /s/ Angus Pacala
Angus Pacala
Co-Founder and Chief Executive Officer
(*principal executive officer*)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Ouster, Inc. (the “Company”) for the period ended June 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2026

By: /s/ Kenneth P. Gianella
Kenneth P. Gianella
Chief Financial Officer
(*principal financial officer*)